{
  "PMC11430164": {
    "pmid": 39346054,
    "pmcid": "PMC11430164",
    "title": "The effect of gene polymorphism on ticagrelor metabolism: an ",
    "study_parameters": {},
    "var_drug_ann": [],
    "var_pheno_ann": [],
    "var_fa_ann": [
      {
        "Variant Annotation ID": 1452626580,
        "Variant/Haplotypes": "CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*19, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "clearance of",
        "Comparison Allele(s) or Genotype(s)": "*1"
      },
      {
        "Variant Annotation ID": 1452626560,
        "Variant/Haplotypes": "CYP3A4*1, CYP3A4*11, CYP3A4*18, CYP3A4*33",
        "Gene": "CYP3A4",
        "Drug(s)": "ticagrelor",
        "PMID": 39346054,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"CYP3A4 variants could be classified into the following three categories according to the relative clearance values compare with CYP3A4*1: CYP3A4*11, CYP3A4*18 and CYP3A4*33 showed significantly higher intrinsic clearance than that of CYP3A4*1; four CYP3A4 variants (CYP3A4*10, CYP3A4*23, CYP3A4*32 and CYP3A4*34) were not significantly different from that of wild-type; the remaining fourteen variants (CYP3A4*2-*5, *9, *14-*17, *19, *24, *28, *29, and *31,) exhibited significantly reduced CLint in different degrees (1.48%\u201375.11% relative clearance) compared to that of wild-type\"",
        "Sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.",
        "Alleles": "*11 + *18 + *33",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Functional terms": "clearance of",
        "Comparison Allele(s) or Genotype(s)": "*1"
      }
    ]
  },
  "PMC10786722": {
    "pmid": 38216550,
    "pmcid": "PMC10786722",
    "title": "Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity.",
    "study_parameters": {
      "Study Parameters ID": 1452352264,
      "Variant Annotation ID": 1452352260,
      "Study Cases": 855.0,
      "Characteristics": "plasma dihydrouracil/uracil",
      "Characteristics Type": "Study Cohort",
      "P Value": "< 0.05",
      "Biogeographical Groups": "Unknown"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [],
    "var_fa_ann": [
      {
        "Variant Annotation ID": 1452352260,
        "Variant/Haplotypes": "rs56038477",
        "Gene": "DPYD",
        "PMID": 38216550,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).\" NOTE: the HapB has two variants, and c.1129-5923C>G rs75017182 is the causative variant, a recent study has shown they are not in perfect LD in all populations [PMID: 38129972].",
        "Sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.",
        "Alleles": "CT + TT",
        "Assay type": "plasma dihydrouracil/uracil",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "activity of",
        "Gene/gene product": "DPYD",
        "Comparison Allele(s) or Genotype(s)": "CC"
      },
      {
        "Variant Annotation ID": 1452352325,
        "Variant/Haplotypes": "rs1801160",
        "Gene": "DPYD",
        "PMID": 38216550,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"The association between common DPYD genetic variants (MAF\u2009\u2265\u20091%) and DPD activity is summarized in Fig. 2. Among the seven genetic variants identified, three variants (c.1236G>A or rs56038477 p.Glu412Glu ; c.496A>G or rs2297595 p.Met166Val; DPYD*6 c.2194G>A or rs1801160 p.Val732Ile) were significantly more frequent in the group of patients exhibiting partial DPD deficiency. Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).",
        "Sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.",
        "Alleles": "CT + TT",
        "Assay type": "plasma dihydrouracil/uracil",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "activity of",
        "Gene/gene product": "DPYD",
        "Comparison Allele(s) or Genotype(s)": "CC"
      },
      {
        "Variant Annotation ID": 1452352320,
        "Variant/Haplotypes": "rs2297595",
        "Gene": "DPYD",
        "PMID": 38216550,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"The association between common DPYD genetic variants (MAF\u2009\u2265\u20091%) and DPD activity is summarized in Fig. 2. Among the seven genetic variants identified, three variants (c.1236G>A or rs56038477 p.Glu412Glu ; c.496A>G or rs2297595 p.Met166Val; DPYD*6 c.2194G>A or rs1801160 p.Val732Ile) were significantly more frequent in the group of patients exhibiting partial DPD deficiency. Consistent with previous reports, the c.1236G>A (rs56038477) which is included in the risk haplotype B3 was significantly associated with low DPD activity [30, 31]. Nevertheless, compared to the most clinically relevant DPYD defective variants, the association of these three variants with DPD activity was rather modest (Fig. 2).",
        "Sentence": "Genotypes CC + CT is associated with decreased activity of DPYD as compared to genotype TT.",
        "Alleles": "CC + CT",
        "Assay type": "plasma dihydrouracil/uracil",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Functional terms": "activity of",
        "Gene/gene product": "DPYD",
        "Comparison Allele(s) or Genotype(s)": "TT"
      }
    ]
  },
  "PMC10993165": {
    "pmid": 38568509,
    "pmcid": "PMC10993165",
    "title": "Human Leukocyte Antigens and Sulfamethoxazole/Cotrimoxazole-Induced Severe Cutaneous Adverse Reactions: A Systematic Review and Meta-Analysis.",
    "study_parameters": {
      "Study Parameters ID": 1452437426,
      "Variant Annotation ID": 1452437420,
      "Study Type": "meta-analysis",
      "Study Cases": 158.0,
      "Study Controls": 226.0,
      "Characteristics": "2 studies, SCAR v tolerant controls",
      "Characteristics Type": "Study Cohort",
      "P Value": "= 0.01",
      "Ratio Stat Type": "OR",
      "Ratio Stat": 2.23,
      "Confidence Interval Start": 1.2,
      "Confidence Interval Stop": 4.14,
      "Biogeographical Groups": "Multiple groups"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1452437420,
        "Variant/Haplotypes": "HLA-B*15:02",
        "Gene": "HLA-B",
        "Drug(s)": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
        "PMID": 38568509,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"The associations between patients with SMX/CTX-induced SCARs and different HLA alleles are presented in Figure 2, Table 2, and eTable 3 in Supplement 1. Significant associations were found in HLA-A*11:01 (OR, 2.10; 95% CI, 1.11-4.00), HLA-B*13:01 (OR, 5.96; 95% CI, 1.58-22.56), HLA-B*15:02 (OR, 2.23; 95% CI, 1.20-4.14), HLA-B*38:02 (OR, 3.47; 95% CI, 1.42-8.48), and HLA-C*08:01 (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls. \"In the Stevens-Johnson syndrome/toxic epidermal necrolysis subgroup, significant associations were found in HLA-B*15:02 (OR, 3.01; 95% CI, 1.56-5.80) and HLA-B*38:02 (OR, 5.13; 95% CI, 1.96-13.47). \"",
        "Sentence": "HLA-B *15:02 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.",
        "Alleles": "*15:02",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or"
      },
      {
        "Variant Annotation ID": 1452438980,
        "Variant/Haplotypes": "HLA-B*13:01",
        "Gene": "HLA-B",
        "Drug(s)": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
        "PMID": 38568509,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"The associations between patients with SMX/CTX-induced SCARs and different HLA alleles are presented in Figure 2, Table 2, and eTable 3 in Supplement 1. Significant associations were found in HLA-A*11:01 (OR, 2.10; 95% CI, 1.11-4.00), HLA-B*13:01 (OR, 5.96; 95% CI, 1.58-22.56), HLA-B*15:02 (OR, 2.23; 95% CI, 1.20-4.14), HLA-B*38:02 (OR, 3.47; 95% CI, 1.42-8.48), and HLA-C*08:01 (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls.\"",
        "Sentence": "HLA-B *13:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.",
        "Alleles": "*13:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or"
      },
      {
        "Variant Annotation ID": 1452439000,
        "Variant/Haplotypes": "HLA-B*38:02",
        "Gene": "HLA-B",
        "Drug(s)": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
        "PMID": 38568509,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"The associations between patients with SMX/CTX-induced SCARs and different HLA alleles are presented in Figure 2, Table 2, and eTable 3 in Supplement 1. Significant associations were found in HLA-A*11:01 (OR, 2.10; 95% CI, 1.11-4.00), HLA-B*13:01 (OR, 5.96; 95% CI, 1.58-22.56), HLA-B*15:02 (OR, 2.23; 95% CI, 1.20-4.14), HLA-B*38:02 (OR, 3.47; 95% CI, 1.42-8.48), and HLA-C*08:01 (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls. \"In the Stevens-Johnson syndrome/toxic epidermal necrolysis subgroup, significant associations were found in HLA-B*15:02 (OR, 3.01; 95% CI, 1.56-5.80) and HLA-B*38:02 (OR, 5.13; 95% CI, 1.96-13.47). \"",
        "Sentence": "HLA-B *38:02 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.",
        "Alleles": "*38:02",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or"
      }
    ],
    "var_fa_ann": []
  },
  "PMC12331468": {
    "pmid": 40786508,
    "pmcid": "PMC12331468",
    "title": "Genetic variants and clinical determinants affecting the response to 5-Fluorouracil-based treatment in Chilean patients with advanced colorectal cancer.",
    "study_parameters": {
      "Study Parameters ID": 1454223606,
      "Variant Annotation ID": 1454223600,
      "Study Cases": 82.0,
      "Characteristics": "neuropathy",
      "Characteristics Type": "Study Cohort",
      "P Value": "= 0.05",
      "Biogeographical Groups": "Latino"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1454223600,
        "Variant/Haplotypes": "rs1801265",
        "Gene": "DPYD",
        "Drug(s)": "FOLFOX, XELOX",
        "PMID": 40786508,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"Further analysis of ungrouped ADRs indicated a higher risk of neuropathy in patients carrying the C allele of the DPYD rs1801265 polymorphism ( Supplementary Table 3 , codominant model T/C genotype OR = 30.0, p-value = 0.0049, dominant model OR = 4.583, p-value = 0.05).\" Alleles complemented.",
        "Sentence": "Genotypes AG + GG is associated with increased likelihood of Peripheral Nervous System Diseases when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotype AA.",
        "Alleles": "AG + GG",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Peripheral Nervous System Diseases",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Colorectal Neoplasms",
        "Comparison Allele(s) or Genotype(s)": "AA"
      },
      {
        "Variant Annotation ID": 1454223640,
        "Variant/Haplotypes": "rs1695",
        "Gene": "GSTP1",
        "Drug(s)": "FOLFOX, XELOX",
        "PMID": 40786508,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"The G allele of the GSTP1 rs1695 polymorphism was correlated with a lower risk of hematological and nervous system disorders in treated patients, including a reduced risk of neuropathy. This was observed through the analysis of individual ADR using univariate logistic regression without CTCAE v5.0 grouping ( Supplementary Table 3 , OR = 0.01, p-value = 0.008). However, we observed a higher risk of mucositis in patients carrying this polymorphism ( Supplementary Table 3 , OR = 2.27, p-value = 0.036).\"",
        "Sentence": "Genotype GG is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.",
        "Alleles": "GG",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Peripheral Nervous System Diseases, Side Effect:Myelosuppression",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Colorectal Neoplasms",
        "Comparison Allele(s) or Genotype(s)": "AA + AG"
      },
      {
        "Variant Annotation ID": 1454223652,
        "Variant/Haplotypes": "rs11280056",
        "Gene": "TYMS",
        "Drug(s)": "FOLFOX, XELOX",
        "PMID": 40786508,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"TYMS 3\u2019UTR 6bp deletion (rs11280056) was the only polymorphism associated with a lower risk of severe hematological disorders (dominant model OR = 0,098, CI 95% 0.013 \u2013 0.441, p-value =0.005).\"",
        "Sentence": "Genotypes TTA/TTA + TTA/TTAAAGTTA is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms.",
        "Alleles": "TTA/TTA + TTA/TTAAAGTTA",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Peripheral Nervous System Diseases, Side Effect:Myelosuppression",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Colorectal Neoplasms"
      },
      {
        "Variant Annotation ID": 1454223625,
        "Variant/Haplotypes": "rs45445694",
        "Gene": "TYMS",
        "Drug(s)": "FOLFOX, XELOX",
        "PMID": 40786508,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"3R genotype of TYMS 5\u2019UTR (rs45445694) is associated as a risk factor for skin and subcutaneous tissue disorders (OR = 6.40; p = 0.029).\"",
        "Sentence": "Genotype (GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3 is associated with increased likelihood of Hand-foot syndrome, Exanthema or Drug Toxicity when treated with FOLFOX or XELOX in people with Colorectal Neoplasms.",
        "Alleles": "(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Hand-foot syndrome, Side Effect:Exanthema, Side Effect:Drug Toxicity",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Colorectal Neoplasms"
      },
      {
        "Variant Annotation ID": 1454223701,
        "Variant/Haplotypes": "rs1695",
        "Gene": "GSTP1",
        "Drug(s)": "FOLFOX, XELOX",
        "PMID": 40786508,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"The G allele of the GSTP1 rs1695 polymorphism was correlated with a lower risk of hematological and nervous system disorders in treated patients, including a reduced risk of neuropathy. This was observed through the analysis of individual ADR using univariate logistic regression without CTCAE v5.0 grouping ( Supplementary Table 3 , OR = 0.01, p-value = 0.008). However, we observed a higher risk of mucositis in patients carrying this polymorphism ( Supplementary Table 3 , OR = 2.27, p-value = 0.036).\"",
        "Sentence": "Genotype GG is associated with increased likelihood of Mucositis when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.",
        "Alleles": "GG",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Mucositis",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Colorectal Neoplasms",
        "Comparison Allele(s) or Genotype(s)": "AA + AG"
      }
    ],
    "var_fa_ann": []
  },
  "PMC12319246": {
    "pmid": 40761554,
    "pmcid": "PMC12319246",
    "title": "Pharmacogenetics association with long-term clinical evolution in a kidney transplant patients cohort.",
    "study_parameters": {
      "Study Parameters ID": 1454211336,
      "Variant Annotation ID": 1454211330,
      "Study Cases": 79.0,
      "Characteristics": "acute rejection during 12-year follow-up, recipient",
      "Characteristics Type": "Study Cohort",
      "P Value": "= 0.047",
      "Biogeographical Groups": "Unknown"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1454211330,
        "Variant/Haplotypes": "rs2740574",
        "Gene": "CYP3A4",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "\"Regarding acute rejection, statistical analysis showed that the CYP3A4 rs2740574 AA variant in the recipient could offer a protective effect (OR: 0.080; p-value: 0.047) compared to other variants at that location. \" Alleles complemented.",
        "Sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.",
        "Alleles": "TT",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Transplant rejection",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Comparison Allele(s) or Genotype(s)": "CC + CT"
      },
      {
        "Variant Annotation ID": 1454211347,
        "Variant/Haplotypes": "rs3745274",
        "Gene": "CYP2B6",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "\"The presence of the TT variant in SLCO1B1 rs4149056 in the recipient and the GT variant in CYP2B6 rs3745274 in the donor were also statistically associated with a reduced risk (OR: 0.16 and 0.2, respectively) of acute rejection.\"",
        "Sentence": "Genotype GT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.",
        "Alleles": "GT",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Transplant rejection",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation"
      },
      {
        "Variant Annotation ID": 1454211400,
        "Variant/Haplotypes": "rs2306283",
        "Gene": "SLCO1B1",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "From Table 3. AA and AG genotype of Recipient and AG genotype of donor were association with lower odds of nephrotoxicity",
        "Sentence": "Genotypes AA + AG is associated with decreased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.",
        "Alleles": "AA + AG",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Nephrotoxicity",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation"
      },
      {
        "Variant Annotation ID": 1454211260,
        "Variant/Haplotypes": "rs9282564",
        "Gene": "ABCB1",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "\"The AA variant in the rs9282564 SNP of the donor's ABCB1 gene was significantly associated (p-value: 0.029) with a reduced risk (OR: 0.116) of exitus during the follow-up period.\" \"The AG variant in ABCB1 gene rs9282564 of the donor was significantly associated (p-value: 0.042; log-rank) with reduced cumulative survival compared to the AA variant (Fig. 1A).\" Alleles complemented.",
        "Sentence": "Genotype TT is associated with decreased risk of Death when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.",
        "Alleles": "TT",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Efficacy:Death",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Comparison Allele(s) or Genotype(s)": "CC + CT"
      },
      {
        "Variant Annotation ID": 1454211271,
        "Variant/Haplotypes": "rs2273697",
        "Gene": "ABCC2",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "\"patients receiving a graft from a donor with the GA genotype in rs2273697 of ABCC2 were significantly associated (p-value: 0.021) with an increased risk (OR: 4.133) of exitus.\" \" It was observed that the genotype in the donor's ABCC2 rs2273697 could significantly (p-value: 0.003; log-rank) affect survival (Fig. 1B), with the GG variant providing a higher rate during the entire follow-up compared to AA and GA.\"",
        "Sentence": "Genotype GG is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.",
        "Alleles": "GG",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Overall survival",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Comparison Allele(s) or Genotype(s)": "AA + AG"
      },
      {
        "Variant Annotation ID": 1454211280,
        "Variant/Haplotypes": "rs776746",
        "Gene": "CYP3A5",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Efficacy",
        "Significance": "no",
        "Notes": "\"Although the CYP3A5 rs776746 did not show a significant association with survival in logistic regression, the Kaplan-Meier curve was also represented (Fig. 1C) due to its special relevance and clinical evidence on the response to tacrolimus. No significant difference was observed by log-rank either, but it should not be discarded that the GG variant (\u22173/\u22173) could offer an advantage, especially at late post-transplantation stages.\" Alleles complemented. No *1*1 shown on kaplan meier, graph marked as recipient",
        "Sentence": "Genotype CC is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CT.",
        "Alleles": "CC",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Overall survival",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation",
        "Comparison Allele(s) or Genotype(s)": "CT"
      },
      {
        "Variant Annotation ID": 1454211340,
        "Variant/Haplotypes": "rs4149056",
        "Gene": "SLCO1B1",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "\"The presence of the TT variant in SLCO1B1 rs4149056 in the recipient and the GT variant in CYP2B6 rs3745274 in the donor were also statistically associated with a reduced risk (OR: 0.16 and 0.2, respectively) of acute rejection.\" \"Recipients with the TT variant in SLCO1B1 rs4149056 showed higher dose-adjusted tacrolimus concentrations, possibly mediating a greater immunosuppressive effect and protecting against rejection, consistent with our logistic regression results (OR: 0.157). \"",
        "Sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.",
        "Alleles": "TT",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Transplant rejection",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation"
      },
      {
        "Variant Annotation ID": 1454211323,
        "Variant/Haplotypes": "rs4244285",
        "Gene": "CYP2C19",
        "Drug(s)": "tacrolimus",
        "PMID": 40761554,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"An increased risk of nephrotoxicity was observed in patients receiving grafts carrying the AA variant in CYP2C19 rs4244285.\"",
        "Sentence": "Genotype AA is associated with increased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.",
        "Alleles": "AA",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Nephrotoxicity",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Kidney Transplantation"
      }
    ],
    "var_fa_ann": []
  },
  "PMC12260932": {
    "pmid": 40672687,
    "pmcid": "PMC12260932",
    "title": "Azathioprine Metabolites in Erythrocytes and DNA for Therapy Monitoring in Very Early Onset Inflammatory Bowel Disease Pediatric Patients.",
    "study_parameters": {
      "Study Parameters ID": 1454185885,
      "Variant Annotation ID": 1454185880,
      "Study Cases": 61.0,
      "Characteristics": "Erythrocytes thioguanine nucleotides (TGN)",
      "Characteristics Type": "Study Cohort",
      "Biogeographical Groups": "Unknown"
    },
    "var_drug_ann": [
      {
        "Variant Annotation ID": 1454185880,
        "Variant/Haplotypes": "rs2413739",
        "Gene": "PACSIN2",
        "Drug(s)": "deoxy-thioguanosine triphosphate, thioguanosine triphosphate",
        "PMID": 40672687,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "no",
        "Notes": "\"PACSIN2 rs2413739 (37 wild types, 34 heterozygous, 16 homozygous variants), no significant associations with azathioprine-active metabolites were found\" \"Erythrocytes thioguanine nucleotides (TGN) were measured by HPLC, and leukocytes incorporated deoxythioguanosine (DNA-TG) byLC-MS/MS\"",
        "Sentence": "Allele C is not associated with increased concentrations of deoxy-thioguanosine triphosphate and thioguanosine triphosphate in children with Inflammatory Bowel Diseases as compared to allele T.",
        "Alleles": "C",
        "Specialty Population": "Pediatric",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "increased",
        "PD/PK terms": "concentrations of",
        "Multiple drugs And/or": "and",
        "Population types": "in children with",
        "Population Phenotypes or diseases": "Other:Inflammatory Bowel Diseases",
        "Comparison Allele(s) or Genotype(s)": "T"
      },
      {
        "Variant Annotation ID": 1454185840,
        "Variant/Haplotypes": "rs1142345",
        "Gene": "TPMT",
        "Drug(s)": "deoxy-thioguanosine triphosphate, thioguanosine triphosphate",
        "PMID": 40672687,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"The TPMT rs1142345 variant (76 wild type, 10 heterozygous) was associated with increased concentrations of both DNA-TG and TGN (Kruskal\u2013Wallis p-value = 0.024 and p-value = 0.00038, Figure 6a,b, respectively); \" \"Erythrocytes thioguanine nucleotides (TGN) were measured by HPLC, and leukocytes incorporated deoxythioguanosine (DNA-TG) byLC-MS/MS\"",
        "Sentence": "Genotype CT is associated with increased concentrations of deoxy-thioguanosine triphosphate and thioguanosine triphosphate in children with Inflammatory Bowel Diseases as compared to genotype TT.",
        "Alleles": "CT",
        "Specialty Population": "Pediatric",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "PD/PK terms": "concentrations of",
        "Multiple drugs And/or": "and",
        "Population types": "in children with",
        "Population Phenotypes or diseases": "Other:Inflammatory Bowel Diseases",
        "Comparison Allele(s) or Genotype(s)": "TT"
      },
      {
        "Variant Annotation ID": 1454185900,
        "Variant/Haplotypes": "rs2413739",
        "Gene": "PACSIN2",
        "Drug(s)": "azathioprine",
        "PMID": 40672687,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "\"Moreover, the disease activity score was differently distributed on the basis of PACSIN2 rs2413739 genotype (logistic regression not adjusted for repeated observations p-value = 0.04, Figure S9);\" Figure S9 appears to show increased proportions of CC and CT vs TT in the group described not active vs the group active",
        "Sentence": "Genotypes CC + CT is associated with increased clinical benefit to azathioprine in children with Inflammatory Bowel Diseases as compared to genotype TT.",
        "Alleles": "CC + CT",
        "Specialty Population": "Pediatric",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "PD/PK terms": "clinical benefit to",
        "Population types": "in children with",
        "Population Phenotypes or diseases": "Other:Inflammatory Bowel Diseases",
        "Comparison Allele(s) or Genotype(s)": "TT"
      }
    ],
    "var_pheno_ann": [],
    "var_fa_ann": []
  },
  "PMC10275785": {
    "pmid": 37332933,
    "pmcid": "PMC10275785",
    "title": "Effect of NLRP3 inflammasome genes polymorphism on disease susceptibility and response to TNF-\u03b1 inhibitors in Iraqi patients with rheumatoid arthritis.",
    "study_parameters": {
      "Study Parameters ID": 1452143368,
      "Variant Annotation ID": 1452143360,
      "Study Cases": 66.0,
      "Study Controls": 33.0,
      "Characteristics": "Cases = responders, controls = non-responders",
      "Characteristics Type": "Study Cohort",
      "Frequency In Cases": 0.265,
      "Allele Of Frequency In Cases": "T",
      "Frequency In Controls": 0.647,
      "Allele Of Frequency In Controls": "T",
      "P Value": "< 0.0001",
      "Ratio Stat Type": "OR",
      "Ratio Stat": 0.183,
      "Confidence Interval Start": 0.063,
      "Confidence Interval Stop": 0.531,
      "Biogeographical Groups": "Near Eastern"
    },
    "var_drug_ann": [
      {
        "Variant Annotation ID": 1452143360,
        "Variant/Haplotypes": "rs2043211",
        "Gene": "CARD8",
        "Drug(s)": "etanercept, infliximab",
        "PMID": 37332933,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "caution, this is an A/T SNP in a gene on the minus strand. Authors show T as minor allele which suggests is reported on plus strand. Responders = \u0394DAS-28 \u2265 1.2 and DAS-28 \u2264 3.2, Non-responders = \u0394DAS-28 \u2264 1.2 and DAS28 \u2264 5.1 (Table 1)",
        "Sentence": "Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AT.",
        "Alleles": "TT",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "PD/PK terms": "response to",
        "Multiple drugs And/or": "or",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Rheumatoid arthritis",
        "Comparison Allele(s) or Genotype(s)": "AA + AT"
      },
      {
        "Variant Annotation ID": 1452143400,
        "Variant/Haplotypes": "rs4612666",
        "Gene": "NLRP3",
        "Drug(s)": "etanercept, infliximab",
        "PMID": 37332933,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "Responders = \u0394DAS-28 \u2265 1.2 and DAS-28 \u2264 3.2, Non-responders = \u0394DAS-28 \u2264 1.2 and DAS28 \u2264 5.1 (Table 1)",
        "Sentence": "Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.",
        "Alleles": "TT",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "PD/PK terms": "response to",
        "Multiple drugs And/or": "or",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Rheumatoid arthritis",
        "Comparison Allele(s) or Genotype(s)": "CC + CT"
      }
    ],
    "var_pheno_ann": [],
    "var_fa_ann": []
  },
  "PMC12320098": {
    "pmid": 40762011,
    "pmcid": "PMC12320098",
    "title": "Cytochrome P450 genotype polymorphisms and suboptimal voriconazole serum level in a patient with invasive cerebral fungal infection.",
    "study_parameters": {},
    "var_drug_ann": [],
    "var_pheno_ann": [],
    "var_fa_ann": []
  },
  "PMC5508045": {
    "pmid": 28550460,
    "pmcid": "PMC5508045",
    "title": "The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients.",
    "study_parameters": {
      "Study Parameters ID": 1448624167,
      "Variant Annotation ID": 1448624157,
      "Study Type": "cohort, retrospective",
      "Study Cases": 250.0,
      "Characteristics": "warfarin; CT genotype assoc. w/avg decrease of 9.7 mg, and TT of 18.1 mg vs CC",
      "Characteristics Type": "Drug",
      "Frequency In Cases": 0.832,
      "Allele Of Frequency In Cases": "T",
      "Frequency In Controls": 0.168,
      "Allele Of Frequency In Controls": "C",
      "P Value": "< 0.001",
      "Ratio Stat Type": "OR",
      "Biogeographical Groups": "East Asian"
    },
    "var_drug_ann": [
      {
        "Variant Annotation ID": 1448624157,
        "Variant/Haplotypes": "rs9923231",
        "Gene": "VKORC1",
        "Drug(s)": "warfarin",
        "PMID": 28550460,
        "Phenotype Category": "Dosage",
        "Significance": "yes",
        "Notes": "Please note: alleles have been complemented to the + strand.",
        "Sentence": "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.",
        "Alleles": "CT + TT",
        "isPlural": "Are",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "PD/PK terms": "dose of",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:Atrial Fibrillation, Disease:Heart valve replacement, Disease:Pulmonary Hypertension, Disease:Pulmonary Embolism, Disease:Venous Thrombosis",
        "Multiple phenotypes or diseases And/or": "or",
        "Comparison Allele(s) or Genotype(s)": "CC"
      },
      {
        "Variant Annotation ID": 1448624168,
        "Variant/Haplotypes": "rs1057910",
        "Gene": "CYP2C9",
        "Drug(s)": "warfarin",
        "PMID": 28550460,
        "Phenotype Category": "Dosage",
        "Significance": "yes",
        "Sentence": "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.",
        "Alleles": "AC + CC",
        "isPlural": "Are",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "PD/PK terms": "dose of",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:Atrial Fibrillation, Disease:Heart valve replacement, Disease:Pulmonary Hypertension, Disease:Pulmonary Embolism, Disease:Venous Thrombosis",
        "Multiple phenotypes or diseases And/or": "and",
        "Comparison Allele(s) or Genotype(s)": "AA"
      },
      {
        "Variant Annotation ID": 1448624178,
        "Variant/Haplotypes": "rs2108622",
        "Gene": "CYP4F2",
        "Drug(s)": "warfarin",
        "PMID": 28550460,
        "Phenotype Category": "Dosage",
        "Significance": "yes",
        "Sentence": "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.",
        "Alleles": "TT",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "PD/PK terms": "dose of",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:Atrial Fibrillation, Disease:Heart valve replacement, Disease:Pulmonary Hypertension, Disease:Pulmonary Embolism, Disease:Venous Thrombosis",
        "Multiple phenotypes or diseases And/or": "and",
        "Comparison Allele(s) or Genotype(s)": "CC"
      },
      {
        "Variant Annotation ID": 1448624188,
        "Variant/Haplotypes": "rs887829",
        "Gene": "UGT1A1",
        "Drug(s)": "warfarin",
        "PMID": 28550460,
        "Phenotype Category": "Dosage",
        "Significance": "no",
        "Sentence": "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.",
        "Alleles": "C",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "PD/PK terms": "dose of",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:Atrial Fibrillation, Disease:Heart valve replacement, Disease:Pulmonary Hypertension, Disease:Pulmonary Embolism, Disease:Venous Thrombosis",
        "Multiple phenotypes or diseases And/or": "and",
        "Comparison Allele(s) or Genotype(s)": "T"
      }
    ],
    "var_pheno_ann": [],
    "var_fa_ann": []
  },
  "PMC4706412": {
    "pmid": 26745506,
    "pmcid": "PMC4706412",
    "title": "A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.",
    "study_parameters": {
      "Study Parameters ID": 1447682702,
      "Variant Annotation ID": 1447682700,
      "Study Type": "cohort, retrospective",
      "Study Cases": 255.0,
      "Characteristics": "NCT01318057; CYP4F3 *3 partial reg. coeff. 0.560 (SE 0.2274), adj R sq0.0.673",
      "Characteristics Type": "Study Cohort",
      "Frequency In Cases": 0.115,
      "Allele Of Frequency In Cases": "*3",
      "Frequency In Controls": 0.885,
      "Allele Of Frequency In Controls": "*1",
      "P Value": "= 0.014",
      "Ratio Stat Type": "OR",
      "Biogeographical Groups": "Latino"
    },
    "var_drug_ann": [
      {
        "Variant Annotation ID": 1447682700,
        "Variant/Haplotypes": "CYP4F2*1, CYP4F2*3",
        "Gene": "CYP4F2",
        "Drug(s)": "warfarin",
        "PMID": 26745506,
        "Phenotype Category": "Dosage",
        "Significance": "yes",
        "Notes": "The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: the derivation cohort was 99% male.",
        "Sentence": "CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1.",
        "Alleles": "*3",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "PD/PK terms": "dose of",
        "Comparison Allele(s) or Genotype(s)": "*1"
      },
      {
        "Variant Annotation ID": 1447682605,
        "Variant/Haplotypes": "CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8",
        "Gene": "CYP2C9",
        "Drug(s)": "warfarin",
        "PMID": 26745506,
        "Phenotype Category": "Dosage",
        "Significance": "yes",
        "Notes": "The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: the derivation cohort was 99% male and  \"variables were included in final lin. reg model if p<0.05 or if association with daily warfarin dose was marginally significant 0.05 = p = 0.20 with strong biological plausibility\".",
        "Sentence": "CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1.",
        "Alleles": "*2 + *3 + *8",
        "isPlural": "Are",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "PD/PK terms": "dose of",
        "Comparison Allele(s) or Genotype(s)": "*1"
      },
      {
        "Variant Annotation ID": 1447682688,
        "Variant/Haplotypes": "rs9923231",
        "Gene": "VKORC1",
        "Drug(s)": "warfarin",
        "PMID": 26745506,
        "Phenotype Category": "Dosage",
        "Significance": "yes",
        "Notes": "The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: the derivation cohort was 99% male.",
        "Sentence": "Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.",
        "Alleles": "CT + TT",
        "isPlural": "Are",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "PD/PK terms": "dose of",
        "Comparison Allele(s) or Genotype(s)": "CC"
      },
      {
        "Variant Annotation ID": 1447682722,
        "Variant/Haplotypes": "rs1800566",
        "Gene": "NQO1",
        "Drug(s)": "warfarin",
        "PMID": 26745506,
        "Phenotype Category": "Dosage",
        "Significance": "yes",
        "Notes": "The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: 1) the derivation cohort was 99% male 2) alleles have been complemented to the + chromosomal strand and 3) \"variables were included in final lin. reg model if p<0.05 or if association with daily warfarin dose was marginally significant 0.05 = p = 0.20 with strong biological plausability\".",
        "Sentence": "Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.",
        "Alleles": "AA + AG",
        "isPlural": "Are",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "PD/PK terms": "dose of",
        "Comparison Allele(s) or Genotype(s)": "GG"
      }
    ],
    "var_pheno_ann": [],
    "var_fa_ann": []
  },
  "PMC11603346": {
    "pmid": 39604537,
    "pmcid": "PMC11603346",
    "title": "Association between the CYP2B6 polymorphisms and nonnucleoside reverse transcriptase inhibitors drug-induced liver injury: a systematic review and meta-analysis.",
    "study_parameters": {
      "Study Parameters ID": 1452720988,
      "Variant Annotation ID": 1452720980,
      "Study Type": "meta-analysis",
      "Study Cases": 504.0,
      "Characteristics": "2 studies (Carr, Giacomelli): DILI",
      "Characteristics Type": "Study Cohort",
      "P Value": "= 0.01",
      "Ratio Stat Type": "OR",
      "Ratio Stat": 0.42,
      "Confidence Interval Start": 0.21,
      "Confidence Interval Stop": 0.84,
      "Biogeographical Groups": "Multiple groups, \"The meta-analysis of the link between CYP2B6 genotypes and EFV-induced liver injury was only derived from the African population, as well as NVP-induced liver injury were obtained from only African and Caucasian populations. \""
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1452720980,
        "Variant/Haplotypes": "CYP2B6*1, CYP2B6*6",
        "Gene": "CYP2B6",
        "Drug(s)": "nevirapine",
        "PMID": 39604537,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"According to the results of the sensitivity analysis, the substantial relationships between the CYP2B6 *1/*6 allele and a combination of *1/*6 + *6/*6 alleles with a lower risk of NVP-induced liver injury were not attributable to chance. \"",
        "Sentence": "CYP2B6 *1/*6 + *6/*6 is associated with decreased likelihood of Drug-induced liver injury when treated with nevirapine in people with HIV infectious disease as compared to CYP2B6 *1/*1.",
        "Alleles": "*1/*6 + *6/*6",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Drug-induced liver injury",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:HIV infectious disease",
        "Comparison Allele(s) or Genotype(s)": "*1/*1"
      },
      {
        "Variant Annotation ID": 1452721001,
        "Variant/Haplotypes": "CYP2B6*1, CYP2B6*6",
        "Gene": "CYP2B6",
        "Drug(s)": "efavirenz",
        "PMID": 39604537,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"Compared with normal metabolizers, CYP2B6 *6 carriers were significantly more susceptible to EFV-induced liver injury, with an odds ratio (OR) and 95% confidence interval (CI) of 1.83 (1.15\u20132.90), 2.48 (1.28\u20134.79), and 1.94 (1.24\u20133.01) for heterozygous, homozygous, and combination of both alleles, respectively, as well as P value less than 0.05 (Table 2).\"",
        "Sentence": "CYP2B6 *1/*6 + *6/*6 is associated with increased likelihood of Drug-induced liver injury when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 *1/*1.",
        "Alleles": "*1/*6 + *6/*6",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Drug-induced liver injury",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:HIV infectious disease",
        "Comparison Allele(s) or Genotype(s)": "*1/*1"
      }
    ],
    "var_fa_ann": []
  },
  "PMC2859392": {
    "pmid": 20338069,
    "pmcid": "PMC2859392",
    "title": "Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults.",
    "study_parameters": {
      "Study Parameters ID": 1448993668,
      "Variant Annotation ID": 1448993666,
      "Study Type": "cohort",
      "Study Cases": 65.0,
      "Characteristics": "HIV-1/TB co-infected receiving efavirenz-based ART and an anti-TB drug regimen.",
      "Characteristics Type": "Study Cohort",
      "Frequency In Cases": 0.62,
      "Allele Of Frequency In Cases": "G",
      "P Value": "> 0.05",
      "Ratio Stat Type": "OR",
      "Biogeographical Groups": "East Asian"
    },
    "var_drug_ann": [
      {
        "Variant Annotation ID": 1448993666,
        "Variant/Haplotypes": "rs3745274",
        "Gene": "CYP2B6",
        "Drug(s)": "efavirenz",
        "PMID": 20338069,
        "Phenotype Category": "Efficacy",
        "Significance": "no",
        "Notes": "No significant difference in median CD4 T cell counts of each genotype at different time points was seen in efavirenz group (p = 0.818, 0.838, 0.783, 0.753 and 0.587 for baseline, weeks 12, 24, 36 and 48 of ART, respectively).",
        "Sentence": "Genotype TT is not associated with response to efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.",
        "Alleles": "TT",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "PD/PK terms": "response to",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease, Disease:Tuberculosis",
        "Multiple phenotypes or diseases And/or": "and",
        "Comparison Allele(s) or Genotype(s)": "GG + GT"
      },
      {
        "Variant Annotation ID": 1184988061,
        "Variant/Haplotypes": "rs3745274",
        "Gene": "CYP2B6",
        "Drug(s)": "efavirenz",
        "PMID": 20338069,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "Association with significantly increased efavirenz plasma levels. Was significant at week 6, 12 of treatment and 1 month after rifampicin discontinuation.",
        "Sentence": "Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.",
        "Alleles": "TT",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "PD/PK terms": "metabolism of",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease, Disease:Tuberculosis",
        "Multiple phenotypes or diseases And/or": "and",
        "Comparison Allele(s) or Genotype(s)": "GG + GT"
      }
    ],
    "var_pheno_ann": [],
    "var_fa_ann": []
  },
  "PMC10399933": {
    "pmid": 37490620,
    "pmcid": "PMC10399933",
    "title": "Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.",
    "study_parameters": {
      "Study Parameters ID": 1452196130,
      "Variant Annotation ID": 1452196120,
      "Study Cases": 70.0,
      "Characteristics": "Statin switch, fluvastatin",
      "Characteristics Type": "Study Cohort",
      "P Value": "= 0.394",
      "Ratio Stat Type": "Unknown",
      "Biogeographical Groups": "European"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1452196120,
        "Variant/Haplotypes": "CYP2C9*1, CYP2C9*2, CYP2C9*3",
        "Gene": "CYP2C9",
        "Drug(s)": "fluvastatin",
        "PMID": 37490620,
        "Phenotype Category": "Toxicity",
        "Significance": "no",
        "Notes": "effect is described as \"Statin switch\" as measured by changes in prescription refills in the medical record, and attributed to muscle side effects (therefore tagged as toxicity). \"The sample sizes for fluvastatin and pravastatin were relatively small\"\"No statistically significant association was found for fluvastatin\"",
        "Sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .",
        "Alleles": "*2/*2 + *2/*3 + *3/*3",
        "Metabolizer types": "poor metabolizer",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Discontinuation",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *1/*3",
        "Comparison Metabolizer types": "normal metabolizer and intermediate metabolizer"
      },
      {
        "Variant Annotation ID": 1452196040,
        "Variant/Haplotypes": "rs4149056",
        "Gene": "SLCO1B1",
        "Drug(s)": "atorvastatin, fluvastatin, rosuvastatin",
        "PMID": 37490620,
        "Phenotype Category": "Toxicity",
        "Significance": "no",
        "Notes": "effect is described as \"Statin switch\" as measured by changes in prescription refills in the medical record, and attributed to muscle side effects (therefore tagged as toxicity). \"No significant association was observed with atorvastatin and rosuvastatin.\" \"The sample sizes for fluvastatin and pravastatin were relatively small\"\"No statistically significant association was found for fluvastatin\"",
        "Sentence": "Genotypes CC + CT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype TT.",
        "Alleles": "CC + CT",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Discontinuation",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Comparison Allele(s) or Genotype(s)": "TT"
      },
      {
        "Variant Annotation ID": 1452196080,
        "Variant/Haplotypes": "rs2231142",
        "Gene": "ABCG2",
        "Drug(s)": "atorvastatin, fluvastatin, rosuvastatin",
        "PMID": 37490620,
        "Phenotype Category": "Toxicity",
        "Significance": "no",
        "Notes": "effect is described as \"Statin switch\" as measured by changes in prescription refills in the medical record, and attributed to muscle side effects (therefore tagged as toxicity). \"No significant association was observed with atorvastatin and rosuvastatin.\" \"The sample sizes for fluvastatin and pravastatin were relatively small\"\"No statistically significant association was found for fluvastatin\" Alleles complemented to plus chromosomal strand.",
        "Sentence": "Genotypes GT + TT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype GG.",
        "Alleles": "GT + TT",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Discontinuation",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "or",
        "Comparison Allele(s) or Genotype(s)": "GG"
      },
      {
        "Variant Annotation ID": 1452195940,
        "Variant/Haplotypes": "rs4149056",
        "Gene": "SLCO1B1",
        "Drug(s)": "simvastatin",
        "PMID": 37490620,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "effect is described as \"Statin switch\" and \"Statin switch + CK measurement\" as measured by changes in prescription refills in the medical record and order of creatinine kinase labs, and attributed to muscle side effects (therefore tagged as toxicity). \"We confirmed the association of SLCO1B1 c.521C/C genotype with simvastatin intolerance both by using phenotype of switching initial statin to another as a marker of statin intolerance\"",
        "Sentence": "Genotype CC is associated with increased risk of discontinuation when treated with simvastatin as compared to genotype TT.",
        "Alleles": "CC",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Discontinuation",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Comparison Allele(s) or Genotype(s)": "TT"
      },
      {
        "Variant Annotation ID": 1452195947,
        "Variant/Haplotypes": "rs4149056",
        "Gene": "SLCO1B1",
        "Drug(s)": "pravastatin",
        "PMID": 37490620,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "effect is described as \"Statin switch\" as measured by changes in prescription refills in the medical record, and attributed to muscle side effects (therefore tagged as toxicity). \"The sample sizes for fluvastatin and pravastatin were relatively small, but SLCO1B1 c.521T>C carriers had an increased risk of pravastatin intolerance defined by statin switching when compared to homozygous reference T/T genotype\"",
        "Sentence": "Genotypes CC + CT is associated with increased risk of discontinuation when treated with pravastatin as compared to genotype TT.",
        "Alleles": "CC + CT",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Discontinuation",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Comparison Allele(s) or Genotype(s)": "TT"
      }
    ],
    "var_fa_ann": []
  },
  "PMC12038368": {
    "pmid": 40297930,
    "pmcid": "PMC12038368",
    "title": "Impacts of Pharmacokinetic Gene Polymorphisms on Steady-State Plasma Concentrations of Simvastatin in Thai Population.",
    "study_parameters": {
      "Study Parameters ID": 1454052280,
      "Variant Annotation ID": 1454052260,
      "Study Cases": 89.0,
      "Characteristics": "12h simvastatin acid concentrations",
      "Characteristics Type": "Study Cohort",
      "P Value": "= 0.03",
      "Biogeographical Groups": "East Asian"
    },
    "var_drug_ann": [
      {
        "Variant Annotation ID": 1454052260,
        "Variant/Haplotypes": "rs4149056",
        "Gene": "SLCO1B1",
        "Drug(s)": "simvastatin acid",
        "PMID": 40297930,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"The results showed that patients with the SLCO1B1 c.521T>C (rs4149056) TC+CC genotype exhibited higher steady\u2010state plasma levels of simvastatin acid (SVA) compared to TT carriers at a dose of 10\u2009mg/day (5.83 vs. 1.95\u2009ng/mL, p\u2009=\u20090.06).\"",
        "Sentence": "Genotypes CC + CT is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype TT.",
        "Alleles": "CC + CT",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "PD/PK terms": "concentrations of",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Cardiovascular Disease, Other:Dyslipidaemia",
        "Multiple phenotypes or diseases And/or": "or",
        "Comparison Allele(s) or Genotype(s)": "TT"
      },
      {
        "Variant Annotation ID": 1454052282,
        "Variant/Haplotypes": "rs2306283",
        "Gene": "SLCO1B1",
        "Drug(s)": "simvastatin acid",
        "PMID": 40297930,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "\"Additionally, SLCO1B1 rs2306283 was associated with significantly higher SVA levels in patients carrying the G allele (AG+GG genotype) at the same dose (3.63 vs. 1.59\u2009ng/mL, p\u2009=\u20090.04). \"",
        "Sentence": "Genotypes AG + GG is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype AA.",
        "Alleles": "AG + GG",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "PD/PK terms": "concentrations of",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Cardiovascular Disease, Other:Dyslipidaemia",
        "Multiple phenotypes or diseases And/or": "or",
        "Comparison Allele(s) or Genotype(s)": "AA"
      }
    ],
    "var_pheno_ann": [],
    "var_fa_ann": []
  },
  "PMC4916189": {
    "pmid": 26715213,
    "pmcid": "PMC4916189",
    "title": "Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600\u00a0mg in Treatment-Na\u00efve HIV-Infected Patients at 96\u00a0Weeks: Results of the ENCORE1 Study.",
    "study_parameters": {
      "Study Parameters ID": 1448993785,
      "Variant Annotation ID": 1448993783,
      "Study Type": "cohort, clinical trial",
      "Study Cases": 569.0,
      "Characteristics Type": "Unknown",
      "P Value": "= 0.016",
      "Ratio Stat Type": "OR",
      "Biogeographical Groups": "Multiple groups"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1448993783,
        "Variant/Haplotypes": "CYP2B6*1, CYP2B6*9",
        "Gene": "CYP2B6",
        "Drug(s)": "efavirenz",
        "PMID": 26715213,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Sentence": "CYP2B6 *9 is associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.",
        "Alleles": "*9",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Discontinuation",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease",
        "Comparison Allele(s) or Genotype(s)": "*1/*1"
      },
      {
        "Variant Annotation ID": 1448993767,
        "Variant/Haplotypes": "rs3745274",
        "Gene": "CYP2B6",
        "Drug(s)": "efavirenz",
        "PMID": 26715213,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Sentence": "Genotypes GT + TT are associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotype GG.",
        "Alleles": "GT + TT",
        "isPlural": "Are",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Discontinuation",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease",
        "Comparison Allele(s) or Genotype(s)": "GG"
      },
      {
        "Variant Annotation ID": 1448993794,
        "Variant/Haplotypes": "rs2472677",
        "Gene": "NR1I2",
        "Drug(s)": "efavirenz",
        "PMID": 26715213,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Sentence": "Genotype TT is associated with decreased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotypes CC + CT.",
        "Alleles": "TT",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Discontinuation",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease",
        "Comparison Allele(s) or Genotype(s)": "CC + CT"
      },
      {
        "Variant Annotation ID": 1448993759,
        "Variant/Haplotypes": "rs3745274",
        "Gene": "CYP2B6",
        "Drug(s)": "efavirenz",
        "PMID": 26715213,
        "Phenotype Category": "Efficacy",
        "Significance": "no",
        "Notes": "This is not associated with virological endpoint (achieving pVL < 200 copies/mL).",
        "Sentence": "Allele T is not associated with virological response when treated with efavirenz in people with HIV Infections as compared to allele G.",
        "Alleles": "T",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Phenotype": "Efficacy:virological response",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease",
        "Comparison Allele(s) or Genotype(s)": "G"
      },
      {
        "Variant Annotation ID": 1448993831,
        "Variant/Haplotypes": "rs1045642",
        "Gene": "ABCB1",
        "Drug(s)": "efavirenz",
        "PMID": 26715213,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Sentence": "Genotype AA are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.",
        "Alleles": "AA",
        "isPlural": "Are",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Central Nervous System Disorder",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease",
        "Comparison Allele(s) or Genotype(s)": "GG"
      },
      {
        "Variant Annotation ID": 1448993810,
        "Variant/Haplotypes": "rs28399499",
        "Gene": "CYP2B6",
        "Drug(s)": "efavirenz",
        "PMID": 26715213,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Sentence": "Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT.",
        "Alleles": "CC + CT",
        "isPlural": "Are",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Central Nervous System Disorder",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease",
        "Comparison Allele(s) or Genotype(s)": "TT"
      },
      {
        "Variant Annotation ID": 1448993820,
        "Variant/Haplotypes": "rs4803419",
        "Gene": "CYP2B6",
        "Drug(s)": "efavirenz",
        "PMID": 26715213,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Sentence": "Genotypes CT + TT are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype CC.",
        "Alleles": "CT + TT",
        "isPlural": "Are",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Central Nervous System Disorder",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease",
        "Comparison Allele(s) or Genotype(s)": "CC"
      }
    ],
    "var_fa_ann": []
  },
  "PMC6714829": {
    "pmid": 30336686,
    "pmcid": "PMC6714829",
    "title": "Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia.",
    "study_parameters": {
      "Study Parameters ID": 1451226980,
      "Variant Annotation ID": 1451226960,
      "Study Type": "cohort",
      "Study Cases": 542.0,
      "Characteristics Type": "Unknown",
      "P Value": "= 0.016",
      "Biogeographical Groups": "East Asian"
    },
    "var_drug_ann": [
      {
        "Variant Annotation ID": 1451226960,
        "Variant/Haplotypes": "rs4149056",
        "Gene": "SLCO1B1",
        "Drug(s)": "simvastatin",
        "PMID": 30336686,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "Patients carrying 521TT genotype had greater TC and LDL-C reduction in response to simvastatin after 4 weeks of treatment.",
        "Sentence": "Genotype TT is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.",
        "Alleles": "TT",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "PD/PK terms": "response to",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Hypercholesterolemia",
        "Comparison Allele(s) or Genotype(s)": "CC + CT"
      },
      {
        "Variant Annotation ID": 1451227020,
        "Variant/Haplotypes": "rs2306283",
        "Gene": "SLCO1B1",
        "Drug(s)": "simvastatin",
        "PMID": 30336686,
        "Phenotype Category": "Efficacy",
        "Significance": "no",
        "Notes": "Patients carrying 388G allele alone is not significantly associated with greater TC and LDL-C reduction in response to simvastatin after 4 weeks of treatment. no significant associations were found between the 521T>C and 388A>G polymorphisms and the lipid-lowering effects of simvastatin treatment after 8 weeks.",
        "Sentence": "Genotypes AG + GG are not associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.",
        "Alleles": "AG + GG",
        "isPlural": "Are",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "increased",
        "PD/PK terms": "response to",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Hypercholesterolemia",
        "Comparison Allele(s) or Genotype(s)": "AA"
      }
    ],
    "var_pheno_ann": [],
    "var_fa_ann": []
  },
  "PMC10946077": {
    "pmid": 38497131,
    "pmcid": "PMC10946077",
    "title": "Individual Irinotecan Therapy Under the Guidance of Pre-Treated ",
    "study_parameters": {
      "Study Parameters ID": 1452426880,
      "Variant Annotation ID": 1452426860,
      "Study Cases": 110.0,
      "Characteristics": "OS for *6",
      "Characteristics Type": "Study Cohort",
      "P Value": "= 0.703",
      "Biogeographical Groups": "Unknown"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1452426860,
        "Variant/Haplotypes": "UGT1A1*1, UGT1A1*6, UGT1A1*28",
        "Gene": "UGT1A1",
        "Drug(s)": "irinotecan",
        "PMID": 38497131,
        "Phenotype Category": "Efficacy",
        "Significance": "no",
        "Notes": "\"In this study, we calculated irinotecan dose according to UGT1A1*6 gene polymorphism based on BSA. For patients with GG type, irinotecan was used in full dose. For patients with GA type, irinotecan was used by 20% reduction. For patients with AA type, irinotecan was used by 40% reduction.\" \"Of the 8 patients with UGT1A1*6 AA subtype, 5 had severe toxicity and were subsequently switched to paclitaxel in the following treatment. Three patients received paclitaxel treatment directly.\" \"In the present study, univariable and multivariate analysis revealed no relation between PFS and UGT1A1*6 or UGT1A1*28\"",
        "Sentence": "UGT1A1 *6 + *28 is not associated with decreased likelihood of overall survival or progression-free survival when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.",
        "Alleles": "*6 + *28",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Overall survival, Efficacy:Progression-free survival",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Stomach Neoplasms",
        "Comparison Allele(s) or Genotype(s)": "*1"
      },
      {
        "Variant Annotation ID": 1452426882,
        "Variant/Haplotypes": "UGT1A1*1, UGT1A1*28",
        "Gene": "UGT1A1",
        "Drug(s)": "irinotecan",
        "PMID": 38497131,
        "Phenotype Category": "Toxicity",
        "Significance": "no",
        "Notes": "\"there were no significant differences in diarrhea (p\u2009=\u20090.136), neutropenia (p\u2009=\u20090.991), and leukopenia (p\u2009=\u20090.857) in UGT1A1*28 subgroups.\" \"The frequencies of TA6/TA6, TA6/TA7, TA7/TA7 for UGT1A1*28 and GG, GA, AA genotypes for UGT1A1*6 were 70.9%, 25.5%, 3.6% and 60.9%, 31.8%, 7.3%, respectively (Table 2). Three patients (2.7%) carried double heterozygosity (GA and TA6/TA7). No concurrent homozygous mutations were detected.\"",
        "Sentence": "UGT1A1 *28 is not associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.",
        "Alleles": "*28",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "severity of",
        "Phenotype": "Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Diarrhea",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Stomach Neoplasms",
        "Comparison Allele(s) or Genotype(s)": "*1"
      },
      {
        "Variant Annotation ID": 1452426961,
        "Variant/Haplotypes": "UGT1A1*1, UGT1A1*6",
        "Gene": "UGT1A1",
        "Drug(s)": "irinotecan",
        "PMID": 38497131,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"diarrhea (p\u2009=\u20090.000), neutropenia (p\u2009=\u20090.000), and leukopenia (p\u2009=\u20090.003) were significantly different among UGT1A1*6 subgroups (Table 3). Additionally, grade 3/4 diarrhea, neutropenia, and leukopenia were significantly more common in AA genotype patients compared to GG (2%, 19%, and 24%) or GA (23%, 31%, and 31%) genotype patients, suggesting that that patients with the AA genotype could not tolerate severe toxicity even with reduced doses of irinotecan.diarrhea (p\u2009=\u20090.000), neutropenia (p\u2009=\u20090.000), and leukopenia (p\u2009=\u20090.003) were significantly different among UGT1A1*6 subgroups (Table 3). Additionally, grade 3/4 diarrhea, neutropenia, and leukopenia were significantly more common in AA genotype patients compared to GG (2%, 19%, and 24%) or GA (23%, 31%, and 31%) genotype patients, suggesting that that patients with the AA genotype could not tolerate severe toxicity even with reduced doses of irinotecan.\" \"The frequencies of TA6/TA6, TA6/TA7, TA7/TA7 for UGT1A1*28 and GG, GA, AA genotypes for UGT1A1*6 were 70.9%, 25.5%, 3.6% and 60.9%, 31.8%, 7.3%, respectively (Table 2). Three patients (2.7%) carried double heterozygosity (GA and TA6/TA7). No concurrent homozygous mutations were detected.\"",
        "Sentence": "UGT1A1 *6 is associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.",
        "Alleles": "*6",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "severity of",
        "Phenotype": "Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Diarrhea",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Stomach Neoplasms",
        "Comparison Allele(s) or Genotype(s)": "*1"
      }
    ],
    "var_fa_ann": []
  },
  "PMC11062152": {
    "pmid": 38707740,
    "pmcid": "PMC11062152",
    "title": "Risk Factors for Adverse Events of Nanoliposomal Irinotecan Plus 5-Fluorouracil and L-leucovorin.",
    "study_parameters": {
      "Study Parameters ID": 1452474677,
      "Variant Annotation ID": 1452474670,
      "Study Cases": 29.0,
      "Characteristics": "diarrhea greater than grade 1 during Nanoliposomal irinotecan +  5-fluorouracil (5-FU) and leucovorin treatment",
      "Characteristics Type": "Study Cohort",
      "P Value": "= 0.943",
      "Biogeographical Groups": "East Asian"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1452474670,
        "Variant/Haplotypes": "UGT1A1*1, UGT1A1*6, UGT1A1*28",
        "Gene": "UGT1A1",
        "Drug(s)": "fluorouracil, irinotecan, leucovorin",
        "PMID": 38707740,
        "Phenotype Category": "Toxicity",
        "Significance": "no",
        "Notes": "\"Diarrhea during nal-IRI/FL treatment was observed in seven (24.1%) of 29 patients, who had not been prescribed any antidiarrhea medication at the commencing time of nal-IRI. The rest of seven patients were excluded, since they received loperamide for diarrhea symptoms at the start of therapy. The incidence of grade \u22651 diarrhea in patients with UGT1A1*6 or *28 (\u2013/\u2013), (+/\u2013), and (+/+) were 27.3%, 21.4%, and 25.0%, respectively (Figure 1). Multivariate analysis did not extract any risk factors, which significantly affected the development of diarrhea possibly induced by nal-IRI/FL\"",
        "Sentence": "UGT1A1 *6 + *28 is not associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.",
        "Alleles": "*6 + *28",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Diarrhea",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "and",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Pancreatic Neoplasms, Other:Metastatic neoplasm",
        "Multiple phenotypes or diseases And/or": "and",
        "Comparison Allele(s) or Genotype(s)": "*1/*1"
      },
      {
        "Variant Annotation ID": 1452474678,
        "Variant/Haplotypes": "UGT1A1*1, UGT1A1*6, UGT1A1*28",
        "Gene": "UGT1A1",
        "Drug(s)": "fluorouracil, irinotecan, leucovorin",
        "PMID": 38707740,
        "Phenotype Category": "Toxicity",
        "Significance": "no",
        "Notes": "\"Grade 3 or 4 leukopenia and neutropenia in the UGT1A1*6 or *28 (+/+) group demonstrated an incidence rate of 50.0%, indicating a higher tendency than those in UGT1A1*6 or *28 (\u2013/\u2013) and (+/\u2013) groups at 7.1% and 12.5%, respectively (p=0.085 for each) (Figure 2C and D). Multiple regression analyses revealed that the UGT1A1*6 or *28 (+/+) genotype, high AST value before the nal-IRI/FL therapy, and pancreatic head cancer were significantly associated with decreased white blood cell count (p=0.009, 0.019, and 0.030, respectively) (Table III), and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017)\"",
        "Sentence": "UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.",
        "Alleles": "*6/*6 + *28/*28 + *6/*28",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Neutropenia, Side Effect:Leukopenia",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Multiple drugs And/or": "and",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Pancreatic Neoplasms, Other:Metastatic neoplasm",
        "Multiple phenotypes or diseases And/or": "and",
        "Comparison Allele(s) or Genotype(s)": "*1/*1"
      }
    ],
    "var_fa_ann": []
  },
  "PMC6465603": {
    "pmid": 31024313,
    "pmcid": "PMC6465603",
    "title": null,
    "study_parameters": {
      "Study Parameters ID": 1451237470,
      "Variant Annotation ID": 1451237464,
      "Study Type": "case/control",
      "Study Cases": 12.0,
      "Study Controls": 137.0,
      "Characteristics": "AZA-induced leukopenia in Chinese patients with AIH",
      "Characteristics Type": "Study Cohort",
      "Frequency In Cases": 0.042,
      "Allele Of Frequency In Cases": "C",
      "Frequency In Controls": 0.015,
      "Allele Of Frequency In Controls": "C",
      "P Value": "= 0.283"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1451237464,
        "Variant/Haplotypes": "rs1142345",
        "Gene": "TPMT",
        "Drug(s)": "azathioprine",
        "PMID": 31024313,
        "Phenotype Category": "Toxicity",
        "Significance": "no",
        "Notes": "TPMT\u22173C alleles were only observed in four subjects including 3 patients who were heterozygotes (TC) and 1 patient who was homozygous (CC).Authors state in discussion \"the lack of significance observed for rs1142345 in the present study is likely due to its low prevalence in East Asian populations and the small sample size of our cohort.\"",
        "Sentence": "Allele C is not associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to allele T.",
        "Alleles": "C",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Leukopenia",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Autoimmune hepatitis",
        "Comparison Allele(s) or Genotype(s)": "T"
      },
      {
        "Variant Annotation ID": 1451237500,
        "Variant/Haplotypes": "rs116855232",
        "Gene": "NUDT15",
        "Drug(s)": "azathioprine",
        "PMID": 31024313,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Sentence": "Genotypes CT + TT is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to genotype CC.",
        "Alleles": "CT + TT",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Leukopenia",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Autoimmune hepatitis",
        "Comparison Allele(s) or Genotype(s)": "CC"
      }
    ],
    "var_fa_ann": []
  },
  "PMC8973308": {
    "pmid": 35431360,
    "pmcid": "PMC8973308",
    "title": "Susceptibility to thiopurine toxicity by ",
    "study_parameters": {
      "Study Parameters ID": 1451768400,
      "Variant Annotation ID": 1451768380,
      "Study Type": "cohort",
      "Study Cases": 68.0,
      "Characteristics": "Pediatric ALL",
      "Characteristics Type": "Study Cohort",
      "Biogeographical Groups": "Latino"
    },
    "var_drug_ann": [
      {
        "Variant Annotation ID": 1451768380,
        "Variant/Haplotypes": "rs116855232",
        "Gene": "NUDT15",
        "Drug(s)": "mercaptopurine",
        "PMID": 35431360,
        "Phenotype Category": "Dosage",
        "Significance": "no",
        "Notes": "Authors stated \"Although no statistically significant associations were identified, two of the four patients; heterozygous for NUDT15 required a decrease in 6-MP during the follow-up period. \" No TT homozygotes were observed. \"Studies with a larger population size are needed\"",
        "Sentence": "Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.",
        "Alleles": "CT",
        "Specialty Population": "Pediatric",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "PD/PK terms": "dose of",
        "Population types": "in children with",
        "Population Phenotypes or diseases": "Other:Acute lymphoblastic leukemia",
        "Comparison Allele(s) or Genotype(s)": "CC"
      },
      {
        "Variant Annotation ID": 1451769040,
        "Variant/Haplotypes": "rs1800460",
        "Gene": "TPMT",
        "Drug(s)": "mercaptopurine",
        "PMID": 35431360,
        "Phenotype Category": "Dosage",
        "Significance": "no",
        "Notes": "Authors stated \"Although no statistically significant associations were identified... In the case of rs1800460, of the six heterozygous patients, three required a dosage decrease, and two were also heterozygous for rs1142345.\" No TT homozygotes were observed. \"Studies with a larger population size are needed\"",
        "Sentence": "Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.",
        "Alleles": "CT",
        "Specialty Population": "Pediatric",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "PD/PK terms": "dose of",
        "Population types": "in children with",
        "Population Phenotypes or diseases": "Other:Acute lymphoblastic leukemia",
        "Comparison Allele(s) or Genotype(s)": "CC"
      }
    ],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1451769000,
        "Variant/Haplotypes": "rs1800462",
        "Gene": "TPMT",
        "Drug(s)": "mercaptopurine",
        "PMID": 35431360,
        "Phenotype Category": "Toxicity",
        "Significance": "no",
        "Notes": "Authors stated \"Although no statistically significant associations were identified, ...Concerning the genetic variants of TPMT, for rs1800462, two of the four heterozygous patients presented febrile neutropenia, and the same patients also required discontinuation 6-MP during the first six months of maintenance therapy.\" No GG homozygotes were observed. \"Studies with a larger population size are needed\"",
        "Sentence": "Genotype CG is associated with decreased likelihood of febrile neutropenia and discontinuation when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.",
        "Alleles": "CG",
        "Specialty Population": "Pediatric",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Febrile neutropenia, Side Effect:Discontinuation",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in children with",
        "Population Phenotypes or diseases": "Other:Acute lymphoblastic leukemia",
        "Comparison Allele(s) or Genotype(s)": "CC"
      }
    ],
    "var_fa_ann": []
  },
  "PMC12035587": {
    "pmid": 40099566,
    "pmcid": "PMC12035587",
    "title": "Severe myelosuppression and alopecia after thiopurine initiation in a patient with NUDT15 deficiency.",
    "study_parameters": {
      "Study Parameters ID": 1453076188,
      "Variant Annotation ID": 1453076180,
      "Study Type": "case series",
      "Study Cases": 0.0,
      "Characteristics": "41-year-old South Asian female, severe mercaptopurine toxicity secondary to an inherited NUDT15 protein deficiency, resulting in myelosuppression, hepatotoxicity and alopecia.",
      "Characteristics Type": "Study Cohort",
      "Biogeographical Groups": "Central/South Asian"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1453076180,
        "Variant/Haplotypes": "NUDT15*3",
        "Gene": "NUDT15",
        "Drug(s)": "mercaptopurine",
        "PMID": 40099566,
        "Phenotype Category": "Toxicity",
        "Significance": "no",
        "Notes": "\"case of thiopurine toxicity resulting in severe myelosuppression, hepatotoxicity and alopecia in an individual with homozygous *3/*3 loss-of-function alleles in the NUDT15 gene\"",
        "Sentence": "NUDT15 *3/*3 is associated with increased severity of Myelosuppression, Toxic liver disease and Alopecia when treated with mercaptopurine in women with Leukemia, Promyelocytic, Acute.",
        "Alleles": "*3/*3",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "severity of",
        "Phenotype": "Side Effect:Myelosuppression, Side Effect:Toxic liver disease, Side Effect:Alopecia",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in women with",
        "Population Phenotypes or diseases": "Other:Leukemia, Promyelocytic, Acute"
      }
    ],
    "var_fa_ann": []
  },
  "PMC5561238": {
    "pmid": 28819312,
    "pmcid": "PMC5561238",
    "title": "Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles.",
    "study_parameters": {
      "Study Parameters ID": 1448926057,
      "Variant Annotation ID": 1448926055,
      "Study Type": "case/control",
      "Study Cases": 151.0,
      "Study Controls": 413.0,
      "Characteristics": "NCT00310843)",
      "Characteristics Type": "Study Cohort",
      "Ratio Stat Type": "OR",
      "Ratio Stat": 2.32,
      "Confidence Interval Start": 1.42,
      "Confidence Interval Stop": 3.79,
      "Biogeographical Groups": "Multiple groups"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1448926055,
        "Variant/Haplotypes": "HLA-B*67:01",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
        "Sentence": "HLA-B *67:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*67:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926065,
        "Variant/Haplotypes": "HLA-B*78:01",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
        "Sentence": "HLA-B *78:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*78:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448925992,
        "Variant/Haplotypes": "HLA-B*51:02",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
        "Sentence": "HLA-B *51:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*51:02",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926045,
        "Variant/Haplotypes": "HLA-B*56:06",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
        "Sentence": "HLA-B *56:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*56:06",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926109,
        "Variant/Haplotypes": "HLA-B*39:01",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
        "Sentence": "HLA-B *39:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*39:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448925913,
        "Variant/Haplotypes": "HLA-C*05:09",
        "Gene": "HLA-C",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
        "Sentence": "HLA-C *05:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*05:09",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926229,
        "Variant/Haplotypes": "HLA-B*15:32",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
        "Sentence": "HLA-B *15:32 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*15:32",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448925903,
        "Variant/Haplotypes": "HLA-C*05:01",
        "Gene": "HLA-C",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
        "Sentence": "HLA-C *05:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*05:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448925982,
        "Variant/Haplotypes": "HLA-B*51:01",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
        "Sentence": "HLA-B *51:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*51:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926239,
        "Variant/Haplotypes": "HLA-B*15:35",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
        "Sentence": "HLA-B *15:35 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*15:35",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926169,
        "Variant/Haplotypes": "HLA-B*15:12",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
        "Sentence": "HLA-B *15:12 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*15:12",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926299,
        "Variant/Haplotypes": "HLA-DRB1*08:01",
        "Gene": "HLA-DRB1",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
        "Sentence": "HLA-DRB1 *08:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*08:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448925972,
        "Variant/Haplotypes": "HLA-B*39:10",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
        "Sentence": "HLA-B *39:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*39:10",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926099,
        "Variant/Haplotypes": "HLA-B*38:02",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
        "Sentence": "HLA-B *38:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*38:02",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926089,
        "Variant/Haplotypes": "HLA-B*38:01",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
        "Sentence": "HLA-B *38:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*38:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926289,
        "Variant/Haplotypes": "HLA-DRB1*04:04",
        "Gene": "HLA-DRB1",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
        "Sentence": "HLA-DRB1 *04:04 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*04:04",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926035,
        "Variant/Haplotypes": "HLA-B*56:01",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
        "Sentence": "HLA-B *56:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*56:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448925958,
        "Variant/Haplotypes": "HLA-B*35:05",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-B*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
        "Sentence": "HLA-B *35:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*35:05",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926269,
        "Variant/Haplotypes": "HLA-DRB1*01:02",
        "Gene": "HLA-DRB1",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
        "Sentence": "HLA-DRB1 *01:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*01:02",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926139,
        "Variant/Haplotypes": "HLA-B*39:09",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
        "Sentence": "HLA-B *39:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*39:09",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926159,
        "Variant/Haplotypes": "HLA-B*15:01",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
        "Sentence": "HLA-B *15:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*15:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926209,
        "Variant/Haplotypes": "HLA-B*15:27",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
        "Sentence": "HLA-B *15:27 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*15:27",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448998275,
        "Variant/Haplotypes": "HLA-B*35:10",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-B*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
        "Sentence": "HLA-B *35:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*35:10",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448925883,
        "Variant/Haplotypes": "HLA-C*04:06",
        "Gene": "HLA-C",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
        "Sentence": "HLA-C *04:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*04:06",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926149,
        "Variant/Haplotypes": "HLA-B*57:01",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
        "Sentence": "HLA-B *57:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*57:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448925893,
        "Variant/Haplotypes": "HLA-C*04:07",
        "Gene": "HLA-C",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
        "Sentence": "HLA-C *04:07 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*04:07",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926022,
        "Variant/Haplotypes": "HLA-B*55:02",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
        "Sentence": "HLA-B *55:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*55:02",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926279,
        "Variant/Haplotypes": "HLA-DRB1*01:03",
        "Gene": "HLA-DRB1",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
        "Sentence": "HLA-DRB1 *01:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*01:03",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926012,
        "Variant/Haplotypes": "HLA-B*55:01",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
        "Sentence": "HLA-B *55:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*55:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926075,
        "Variant/Haplotypes": "HLA-B*13:02",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
        "Sentence": "HLA-B *13:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*13:02",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926199,
        "Variant/Haplotypes": "HLA-B*15:25",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
        "Sentence": "HLA-B *15:25 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*15:25",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926129,
        "Variant/Haplotypes": "HLA-B*39:06",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
        "Sentence": "HLA-B *39:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*39:06",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448925873,
        "Variant/Haplotypes": "HLA-C*04:03",
        "Gene": "HLA-C",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
        "Sentence": "HLA-C *04:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*04:03",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926002,
        "Variant/Haplotypes": "HLA-B*54:01",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles that share a common \"E pocket sequence\". The authors do not distinguish between the following HLA-B alleles, which is why the OR is the same: HLA-N*35:05, HLA-B*39:10, HLA-B*51:01/02, HLA-B*54:01, HLA-B*55:01/02, HLA-B*56:01/06, HLA-B*67:01, HLA-B*78:01.",
        "Sentence": "HLA-B *54:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*54:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926259,
        "Variant/Haplotypes": "HLA-DRB1*01:01",
        "Gene": "HLA-DRB1",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
        "Sentence": "HLA-DRB1 *01:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*01:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926249,
        "Variant/Haplotypes": "HLA-B*52:01",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
        "Sentence": "HLA-B *52:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*52:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926309,
        "Variant/Haplotypes": "HLA-DRB1*10:01",
        "Gene": "HLA-DRB1",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary risk of severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-DRB1*01:01/02/03, HLA-DRB1*04:04/05/08/10",
        "Sentence": "HLA-DRB1 *10:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*10:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448925862,
        "Variant/Haplotypes": "HLA-C*04:01",
        "Gene": "HLA-C",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "In one allele logistic regression analyses HLA-C*04:01 was the only allele for which an association with cutaneous manifestations of nevirapine related hypersensitivity was observed across all ancestral groups.",
        "Sentence": "HLA-C *04:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*04:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926119,
        "Variant/Haplotypes": "HLA-B*39:05",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-B alleles which the authors do not distinguish between and is why the OR is the same for the following: HLA-B*13:02, HLA-B*38:01/02, HLA-B*39:01/05/06/09, HLA-B*51:07.",
        "Sentence": "HLA-B *39:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*39:05",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448925923,
        "Variant/Haplotypes": "HLA-C*18:01",
        "Gene": "HLA-C",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Primary predisposition to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine is attributed to a cluster of HLA-C alleles that share a common \"binding groove F pocket\" with HLA-C*04:01. The authors do not distinguish between the following HLA-C alleles, which is why the OR is the same: HLA-C*04:03/06/07, HLA-C*05:01/09, HLA-C*18:0.",
        "Sentence": "HLA-C *18:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*18:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1448926179,
        "Variant/Haplotypes": "HLA-B*15:24",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "Secondary risk protection to severe adverse cutaneous reactions/hypersensitivity (SACR/H) to nevirapine are attributed to several alleles and does not distinguish between them which is why ORs are the same: HLA-B*15:01/12/24/25/27/32/35, HLA-B*52:01",
        "Sentence": "HLA-B *15:24 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*15:24",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1449155757,
        "Variant/Haplotypes": "rs28399499",
        "Gene": "CYP2B6",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "The authors analyze rs28399499 T>C and rs3745274 G>A/T together as \"slow metabolizer\" genotypes.",
        "Sentence": "Allele C is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections as compared to allele T.",
        "Alleles": "C",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease",
        "Comparison Allele(s) or Genotype(s)": "T"
      },
      {
        "Variant Annotation ID": 1449155771,
        "Variant/Haplotypes": "rs3745274",
        "Gene": "CYP2B6",
        "Drug(s)": "nevirapine",
        "PMID": 28819312,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "The authors analyze rs28399499 T>C and rs3745274 G>A/T together as \"slow metabolizer\" genotypes.",
        "Sentence": "Allele T is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections as compared to allele G.",
        "Alleles": "T",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease",
        "Comparison Allele(s) or Genotype(s)": "G"
      }
    ],
    "var_fa_ann": []
  },
  "PMC3839910": {
    "pmid": 23588310,
    "pmcid": "PMC3839910",
    "title": "HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.",
    "study_parameters": {
      "Study Parameters ID": 994166721,
      "Variant Annotation ID": 994166507,
      "Study Type": "case/control",
      "Study Cases": 42.0,
      "Study Controls": 91.0,
      "Characteristics": "pediatric patients from North America with a diverse ethnic background, 42 children with CBZ hypersensitivity and 91 CBZ-tolerant children from across Canada.",
      "Characteristics Type": "Study Cohort",
      "P Value": "= 0.002",
      "Ratio Stat Type": "OR",
      "Ratio Stat": 38.6,
      "Biogeographical Groups": "Multiple groups"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 994166507,
        "Variant/Haplotypes": "HLA-B*15:02",
        "Gene": "HLA-B",
        "Drug(s)": "carbamazepine",
        "PMID": 23588310,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Sentence": "HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.",
        "Alleles": "*15:02",
        "Specialty Population": "Pediatric",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Disease:Stevens-Johnson Syndrome",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in children"
      },
      {
        "Variant Annotation ID": 994531642,
        "Variant/Haplotypes": "HLA-B*15:02",
        "Gene": "HLA-B",
        "Drug(s)": "carbamazepine",
        "PMID": 23588310,
        "Phenotype Category": "Toxicity",
        "Significance": "no",
        "Sentence": "HLA-B *15:02 is not associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.",
        "Alleles": "*15:02",
        "Specialty Population": "Pediatric",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Disease:Maculopapular Exanthema",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in children"
      },
      {
        "Variant Annotation ID": 993944301,
        "Variant/Haplotypes": "HLA-A*31:01",
        "Gene": "HLA-A",
        "Drug(s)": "carbamazepine",
        "PMID": 23588310,
        "Phenotype Category": "Toxicity",
        "Significance": "no",
        "Sentence": "HLA-A *31:01 is not associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.",
        "Alleles": "*31:01",
        "Specialty Population": "Pediatric",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Disease:Stevens-Johnson Syndrome",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in children"
      },
      {
        "Variant Annotation ID": 993813998,
        "Variant/Haplotypes": "HLA-A*31:01",
        "Gene": "HLA-A",
        "Drug(s)": "carbamazepine",
        "PMID": 23588310,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Sentence": "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.",
        "Alleles": "*31:01",
        "Specialty Population": "Pediatric",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Disease:Maculopapular Exanthema",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in children"
      },
      {
        "Variant Annotation ID": 992282434,
        "Variant/Haplotypes": "HLA-A*31:01",
        "Gene": "HLA-A",
        "Drug(s)": "carbamazepine",
        "PMID": 23588310,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Sentence": "HLA-A *31:01 is associated with increased risk of Carbamazepine-induced hypersensitivity syndrome when treated with carbamazepine in children.",
        "Alleles": "*31:01",
        "Specialty Population": "Pediatric",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Carbamazepine-induced hypersensitivity syndrome",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in children"
      },
      {
        "Variant Annotation ID": 994398056,
        "Variant/Haplotypes": "HLA-B*15:02",
        "Gene": "HLA-B",
        "Drug(s)": "carbamazepine",
        "PMID": 23588310,
        "Phenotype Category": "Toxicity",
        "Significance": "no",
        "Sentence": "HLA-B *15:02 is not associated with increased risk of Carbamazepine-induced hypersensitivity syndrome (HSS) when treated with carbamazepine in children.",
        "Alleles": "*15:02",
        "Specialty Population": "Pediatric",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Carbamazepine-induced hypersensitivity syndrome (HSS)",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in children"
      }
    ],
    "var_fa_ann": []
  },
  "PMC384715": {
    "pmid": 15024131,
    "pmcid": "PMC384715",
    "title": "Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.",
    "study_parameters": {
      "Study Parameters ID": 1444877110,
      "Variant Annotation ID": 1444876870,
      "Study Type": "case/control",
      "Study Cases": 18.0,
      "Study Controls": 230.0,
      "Characteristics": "Western Australian HIV Cohort Study; HLA-B*57:01 in combination with rs2227956.",
      "Characteristics Type": "Study Cohort",
      "Frequency In Cases": 0.944,
      "Allele Of Frequency In Cases": "*57:01",
      "Frequency In Controls": 0.004,
      "Allele Of Frequency In Controls": "*57:01",
      "P Value": "< 0.00001",
      "Ratio Stat Type": "OR",
      "Ratio Stat": 3893.0,
      "Biogeographical Groups": "Multiple groups, European, Asian Indian, African, indigenous Australian, Asian"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1444876870,
        "Variant/Haplotypes": "HLA-B*57:01",
        "Gene": "HLA-B",
        "Drug(s)": "abacavir",
        "PMID": 15024131,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "The HLA-B*57:01 allele was present in 94.4% of cases of definite abacavir hypersensitivity compared with 1.7% of abacavir-tolerant controls. When in combination with the rs2227956 T allele (Hsp70-Hom M493T), the strength of the association increased, with this combination being present in 94.4% of cases of abacavir hypersensitivity, compared with 0.43% of controls.",
        "Sentence": "HLA-B *57:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.",
        "Alleles": "*57:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Drug Hypersensitivity",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      }
    ],
    "var_fa_ann": []
  },
  "PMC3113609": {
    "pmid": 21428769,
    "pmcid": "PMC3113609",
    "title": "HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.",
    "study_parameters": {
      "Study Parameters ID": 1184466924,
      "Variant Annotation ID": 1184466922,
      "Study Type": "case/control",
      "Study Cases": 12.0,
      "Study Controls": 257.0,
      "Characteristics Type": "Unknown",
      "P Value": "= 8.0E-5",
      "Ratio Stat Type": "OR",
      "Ratio Stat": 25.93,
      "Confidence Interval Start": 4.93,
      "Confidence Interval Stop": 116.18,
      "Biogeographical Groups": "European"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1184466922,
        "Variant/Haplotypes": "HLA-A*31:01",
        "Gene": "HLA-A",
        "Drug(s)": "carbamazepine",
        "PMID": 21428769,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). 42% (5/9) of subjects with carbamazepine-induced SJS/TEN carried the *31:01 allele, as compared to 4% (10/257) of carbamazepine-tolerant controls.",
        "Sentence": "HLA-A *31:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.",
        "Alleles": "*31:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Disease:Severe Cutaneous Adverse Reactions",
        "When treated with/exposed to/when assayed with": "when treated with"
      },
      {
        "Variant Annotation ID": 1184466916,
        "Variant/Haplotypes": "HLA-A*31:01",
        "Gene": "HLA-A",
        "Drug(s)": "carbamazepine",
        "PMID": 21428769,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "Patients with carbamazepine-induced maculopapular exanthema had an increased frequency of *31:01, as compared to carbamazepine-tolerant controls.",
        "Sentence": "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.",
        "Alleles": "*31:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Disease:Maculopapular Exanthema",
        "When treated with/exposed to/when assayed with": "when treated with"
      },
      {
        "Variant Annotation ID": 1184466909,
        "Variant/Haplotypes": "HLA-A*31:01",
        "Gene": "HLA-A",
        "Drug(s)": "carbamazepine",
        "PMID": 21428769,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "Hypersensitivity syndrome defined as the presence of a rash or liver involvement within 3 months after initiation of carbamazepine treatment, along with a minimum of two of the following manifestations: prolonged recovery phase despite drug withdrawal, fever, involvement of other internal organs, or presence of hematologic abnormalities. Patients who experienced carbamazepine-induced hypersensitivity syndrome had an increased frequency of *31:01, as compared to carbamazepine-tolerant controls.",
        "Sentence": "HLA-A *31:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.",
        "Alleles": "*31:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Disease:Drug Hypersensitivity",
        "When treated with/exposed to/when assayed with": "when treated with"
      }
    ],
    "var_fa_ann": []
  },
  "PMC554812": {
    "pmid": 15743917,
    "pmcid": "PMC554812",
    "title": "HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.",
    "study_parameters": {
      "Study Parameters ID": 1184755119,
      "Variant Annotation ID": 981345654,
      "Study Type": "case/control",
      "Study Cases": 51.0,
      "Study Controls": 135.0,
      "Characteristics": "Cases n= 51, controls = 135 tolerant to allopurinol. Statistics and allele frequencies here are for the HLA-B*5801 extended haplotype: B*5801-C*0302-A*3303-DRB1*0301.",
      "Characteristics Type": "Study Cohort",
      "Frequency In Cases": 0.41,
      "Allele Of Frequency In Cases": "*58:01",
      "Frequency In Controls": 0.07,
      "Allele Of Frequency In Controls": "*58:01",
      "P Value": "= 0.039",
      "Ratio Stat Type": "OR",
      "Ratio Stat": 9.8,
      "Biogeographical Groups": "East Asian"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 981345654,
        "Variant/Haplotypes": "HLA-B*58:01",
        "Gene": "HLA-B",
        "Drug(s)": "allopurinol",
        "PMID": 15743917,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "Note: Alleles HLA-A*3303, HLA-C*0302, HLA-DRB1*0301 were also significantly associated with increased risk, but were in LD and formed an extended haplotype with HLA-B*5801. Chronic renal insufficiency was seen at a significantly higher frequency in patients with allopurinol-induced SCAR compared to allopurinol-tolerant patients p<0.0001 (OR=4.7 (2.3-9.3)).",
        "Sentence": "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
        "Alleles": "*58:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with"
      },
      {
        "Variant Annotation ID": 1184755073,
        "Variant/Haplotypes": "HLA-DRB1*03:01",
        "Gene": "HLA-DRB1",
        "Drug(s)": "allopurinol",
        "PMID": 15743917,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "Note: Alleles HLA-A*3303, HLA-C*0302, HLA-DRB1*0301 were in LD and formed an extended haplotype with HLA-B*5801. Chronic renal insufficiency was seen at a significantly higher frequency in patients with allopurinol-induced SCAR compared to allopurinol-tolerant patients p<0.0001 (OR=4.7 (2.3-9.3)).",
        "Sentence": "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
        "Alleles": "*03:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with"
      },
      {
        "Variant Annotation ID": 1184755032,
        "Variant/Haplotypes": "HLA-C*03:02",
        "Gene": "HLA-C",
        "Drug(s)": "allopurinol",
        "PMID": 15743917,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "Note: Alleles HLA-A*3303, HLA-C*0302, HLA-DRB1*0301 were in LD and formed an extended haplotype with HLA-B*5801. Chronic renal insufficiency was seen at a significantly higher frequency in patients with allopurinol-induced SCAR compared to allopurinol-tolerant patients p<0.0001 (OR=4.7 (2.3-9.3)).",
        "Sentence": "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
        "Alleles": "*03:02",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with"
      },
      {
        "Variant Annotation ID": 1184755056,
        "Variant/Haplotypes": "HLA-A*33:03",
        "Gene": "HLA-A",
        "Drug(s)": "allopurinol",
        "PMID": 15743917,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "Note: Alleles HLA-A*3303, HLA-C*0302, HLA-DRB1*0301 were in LD and formed an extended haplotype with HLA-B*5801. Chronic renal insufficiency was seen at a significantly higher frequency in patients with allopurinol-induced SCAR compared to allopurinol-tolerant patients p<0.0001 (OR=4.7 (2.3-9.3)).",
        "Sentence": "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
        "Alleles": "*33:03",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with"
      },
      {
        "Variant Annotation ID": 1184755144,
        "Variant/Haplotypes": "rs1594",
        "Gene": "CFLAR",
        "Drug(s)": "allopurinol",
        "PMID": 15743917,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "An initial screen of 823 SNPs in the MHC region or in genes related to drug metabolism and immune response for association with allopurinol-induced SCAR. The direction of the association (i.e. which allele was associated with increased risk of SCARs and which allele was associated with decreased risk) was not clear. Unclear whether this was corrected for multiple comparisons or not.",
        "Sentence": "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G.",
        "Alleles": "A",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Comparison Allele(s) or Genotype(s)": "G"
      }
    ],
    "var_fa_ann": []
  },
  "PMC3387531": {
    "pmid": 21505298,
    "pmcid": "PMC3387531",
    "title": "Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.",
    "study_parameters": {
      "Study Parameters ID": 1185002093,
      "Variant Annotation ID": 1185002091,
      "Study Type": "case/control",
      "Study Cases": 52.0,
      "Study Controls": 173.0,
      "Characteristics": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
      "Characteristics Type": "Disease",
      "Frequency In Cases": 0.192,
      "Allele Of Frequency In Cases": "*35:01",
      "Frequency In Controls": 0.043,
      "Allele Of Frequency In Controls": "*35:01",
      "P Value": "= 0.022",
      "Ratio Stat Type": "OR",
      "Ratio Stat": 5.65,
      "Confidence Interval Start": 2.03,
      "Confidence Interval Stop": 15.71,
      "Biogeographical Groups": "East Asian"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1185002091,
        "Variant/Haplotypes": "HLA-B*35:01",
        "Gene": "HLA-B",
        "Drug(s)": "nevirapine",
        "PMID": 21505298,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "The frequency of the HLA-B*35 allele was greater in those with nevirapine-related hepatic adverse events as compared to healthy controls when considering a Thai population. No significant results were seen for Asians (non-Thai), Blacks or Whites (p corrected = 0.053, 1.0, 1.0, respectively). Note that this annotation was done on HLA-B*35:01:01:01 because this was the first *35 allele discovered. p-value corrected for multiple testing.",
        "Sentence": "HLA-B *35:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*35:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Drug Toxicity",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1185002083,
        "Variant/Haplotypes": "HLA-DRB1*01:01",
        "Gene": "HLA-DRB1",
        "Drug(s)": "nevirapine",
        "PMID": 21505298,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "The frequency of the HLA-DRB1*01 allele was greater in those with nevirapine-related hepatic adverse events as compared to healthy controls when considering a White population. No significant results were seen for Asians or Blacks. Note that this annotation was done on HLA-DRB1*01:01:01 because this was the first *01 allele discovered. p-value corrected for multiple testing.",
        "Sentence": "HLA-DRB1 *01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*01:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Drug Toxicity",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1185002071,
        "Variant/Haplotypes": "HLA-C*04:01",
        "Gene": "HLA-C",
        "Drug(s)": "nevirapine",
        "PMID": 21505298,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "The frequency of the HLA-Cw*04 allele was greater in those with nevirapine-related cutaneous adverse events as compared to healthy controls. Note that this annotation was done on HLA-C*04:01:01:01 because this was the first *04 allele discovered. p-value corrected for multiple testing.",
        "Sentence": "HLA-C *04:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
        "Alleles": "*04:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Drug Toxicity",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1185002120,
        "Variant/Haplotypes": "rs3745274",
        "Gene": "CYP2B6",
        "Drug(s)": "nevirapine",
        "PMID": 21505298,
        "Phenotype Category": "Toxicity",
        "Significance": "no",
        "Notes": "The frequency of the T allele was greater in those with nevirapine-related cutaneous adverse events as compared to healthy controls (p=5.5 x 10^-5). However, this association was not significant after correction for multiple testing. This SNP was in LD with rs3876547 and rs2054675 (r2 > 0.90). This SNP was not associated with hepatic adverse events after correcting for multiple comparisons.",
        "Sentence": "Allele T is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
        "Alleles": "T",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Drug Toxicity",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1185002099,
        "Variant/Haplotypes": "rs2054675",
        "Gene": "CYP2B6",
        "Drug(s)": "nevirapine",
        "PMID": 21505298,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "The frequency of the C allele was greater in those with nevirapine-related cutaneous adverse events as compared to healthy controls. This SNP was in LD with rs3876547 (r2 = 0.982) and rs3745274 (r2 > 0.90). p-value corrected for multiple testing. This SNP was not associated with hepatic adverse events after correcting for multiple comparisons.",
        "Sentence": "Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
        "Alleles": "C",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Drug Toxicity",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      },
      {
        "Variant Annotation ID": 1185002114,
        "Variant/Haplotypes": "rs3786547",
        "Gene": "CYP2B6",
        "Drug(s)": "nevirapine",
        "PMID": 21505298,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "The frequency of the C allele was greater in those with nevirapine-related cutaneous adverse events as compared to healthy controls. This SNP was in LD with rs2054674 (r2 = 0.982) and rs3745274 (r2 > 0.90). p-value corrected for multiple testing. This SNP was not associated with hepatic adverse events after correcting for multiple comparisons.",
        "Sentence": "Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
        "Alleles": "C",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Drug Toxicity",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Disease:HIV infectious disease"
      }
    ],
    "var_fa_ann": []
  },
  "PMC8790808": {
    "pmid": 33768542,
    "pmcid": "PMC8790808",
    "title": "Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity.",
    "study_parameters": {
      "Study Parameters ID": 1451510741,
      "Variant Annotation ID": 1451510720,
      "Study Type": "cohort",
      "Study Cases": 402.0,
      "Characteristics": "TXVI cohort",
      "Characteristics Type": "Study Cohort",
      "P Value": "= 3.28e-5",
      "Ratio Stat Type": "OR",
      "Ratio Stat": 2.91,
      "Biogeographical Groups": "European"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1451510720,
        "Variant/Haplotypes": "HLA-DQA1*02:01",
        "Gene": "HLA-DQA1",
        "Drug(s)": "pegaspargase",
        "PMID": 33768542,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "HLA alleles DQB1*02:02, DRB1*07:01, and DQA1*02:01 had significant associations with pegaspargase hypersensitivity (P < 5.0 \u00d7 10-5 ) in patients with primarily European ancestry (EA), with the three alleles associating in a single haplotype.",
        "Sentence": "HLA-DQA1 *02:01 is associated with increased risk of Hypersensitivity when treated with pegaspargase.",
        "Alleles": "*02:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Hypersensitivity",
        "When treated with/exposed to/when assayed with": "when treated with"
      },
      {
        "Variant Annotation ID": 1451510886,
        "Variant/Haplotypes": "HLA-DQB1*02:02",
        "Gene": "HLA-DQB1",
        "Drug(s)": "pegaspargase",
        "PMID": 33768542,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "HLA alleles DQB1*02:02, DRB1*07:01, and DQA1*02:01 had significant associations with pegaspargase hypersensitivity (P < 5.0 \u00d7 10-5 ) in patients with primarily European ancestry (EA), with the three alleles associating in a single haplotype.",
        "Sentence": "HLA-DQB1 *02:02 is associated with increased risk of Hypersensitivity when treated with pegaspargase.",
        "Alleles": "*02:02",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Hypersensitivity",
        "When treated with/exposed to/when assayed with": "when treated with"
      },
      {
        "Variant Annotation ID": 1451510891,
        "Variant/Haplotypes": "HLA-DRB1*07:01",
        "Gene": "HLA-DRB1",
        "Drug(s)": "pegaspargase",
        "PMID": 33768542,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "HLA alleles DQB1*02:02, DRB1*07:01, and DQA1*02:01 had significant associations with pegaspargase hypersensitivity (P < 5.0 \u00d7 10-5 ) in patients with primarily European ancestry (EA), with the three alleles associating in a single haplotype.",
        "Sentence": "HLA-DRB1 *07:01 is associated with increased risk of Hypersensitivity when treated with pegaspargase.",
        "Alleles": "*07:01",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Hypersensitivity",
        "When treated with/exposed to/when assayed with": "when treated with"
      },
      {
        "Variant Annotation ID": 1451510773,
        "Variant/Haplotypes": "rs9958628",
        "Gene": "ARHGAP28",
        "Drug(s)": "pegaspargase",
        "PMID": 33768542,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "This variant is significantly associated with pegaspargase hypersensitivity in all patients and also had the strongest genetic association (P = 8.9 \u00d7 10-9 ) in non-EAs.",
        "Sentence": "Allele T is associated with increased risk of Hypersensitivity when treated with pegaspargase as compared to allele A.",
        "Alleles": "T",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "risk of",
        "Phenotype": "Side Effect:Hypersensitivity",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Comparison Allele(s) or Genotype(s)": "A"
      }
    ],
    "var_fa_ann": []
  },
  "PMC3548984": {
    "pmid": 23213055,
    "pmcid": "PMC3548984",
    "title": "CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.",
    "study_parameters": {
      "Study Parameters ID": 1444933951,
      "Variant Annotation ID": 1444933926,
      "Study Type": "prospective",
      "Study Cases": 166.0,
      "Study Controls": 287.0,
      "Characteristics": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); PM/PM vs EM/EM",
      "Characteristics Type": "Study Cohort",
      "P Value": "= 0.04",
      "Ratio Stat Type": "OR",
      "Ratio Stat": 2.45,
      "Confidence Interval Start": 1.05,
      "Confidence Interval Stop": 5.73,
      "Biogeographical Groups": "European"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1444933926,
        "Variant/Haplotypes": "CYP2D6*1, CYP2D6*3, CYP2D6*4",
        "Gene": "CYP2D6",
        "Drug(s)": "tamoxifen",
        "PMID": 23213055,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "Note: article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist. Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \u201cextensive\u201d metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u201cpoor\u201d metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
        "Sentence": "CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
        "Alleles": "*3/*3 + *4/*4",
        "isPlural": "Are",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Recurrence",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in women with",
        "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
        "Comparison Allele(s) or Genotype(s)": "*1/*1"
      },
      {
        "Variant Annotation ID": 1444933959,
        "Variant/Haplotypes": "CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6",
        "Gene": "CYP2D6",
        "Drug(s)": "tamoxifen",
        "PMID": 23213055,
        "Phenotype Category": "Efficacy",
        "Significance": "no",
        "Notes": "Note: PM/IM genotypes are missing; article did not report all genotypes; only *1/variant allele and homozygous variant allele but no combinations of variant alleles e.g. PM/IM even if phenotype grouping exist.Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \u201cextensive\u201d metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u201cpoor\u201d metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
        "Sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
        "Alleles": "*1/*3 + *1/*4 + *1/*6",
        "isPlural": "Are",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Recurrence",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in women with",
        "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
        "Comparison Allele(s) or Genotype(s)": "*1/*1"
      },
      {
        "Variant Annotation ID": 1444933987,
        "Variant/Haplotypes": "CYP2D6*1, CYP2D6*10, CYP2D6*41",
        "Gene": "CYP2D6",
        "Drug(s)": "tamoxifen",
        "PMID": 23213055,
        "Phenotype Category": "Efficacy",
        "Significance": "no",
        "Notes": "Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \u201cextensive\u201d metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u201cpoor\u201d metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
        "Sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
        "Alleles": "*1/*10 + *1/*41 + *10/*10 + *41/*41",
        "isPlural": "Are",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Recurrence",
        "Multiple phenotypes And/or": "and",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in women with",
        "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
        "Comparison Allele(s) or Genotype(s)": "*1/*1"
      }
    ],
    "var_fa_ann": []
  },
  "PMC3584248": {
    "pmid": 23476897,
    "pmcid": "PMC3584248",
    "title": "CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer.",
    "study_parameters": {
      "Study Parameters ID": 1444930473,
      "Variant Annotation ID": 1444930388,
      "Study Type": "clinical trial",
      "Study Cases": 224.0,
      "Characteristics": "endpoint: endoxifen concentration after 4 month; slow vs normal metabolizer; p = 0.0001 for trend: normal > intermediate > slow",
      "Characteristics Type": "Study Cohort",
      "P Value": "= 0.0001",
      "Ratio Stat Type": "OR",
      "Biogeographical Groups": "East Asian"
    },
    "var_drug_ann": [
      {
        "Variant Annotation ID": 1444930388,
        "Variant/Haplotypes": "CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41",
        "Gene": "CYP2D6",
        "Drug(s)": "endoxifen",
        "PMID": 23476897,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "No information on menopausal status or if tamoxifen only treatment. No co-treatment with CYP2D6 inhibitors CYP2D6 alleles *2, *3, *4, *5, *6, *10, and *41 are genotyped with predeveloped TaqMan Genotyping Assays. Genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2 -*1/*1, *1/*2, *2/*2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41-*1/*10, *2/*10, *1/*41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6-*10/*10, *10/*41, *1/*5, *2/*5, *5/*10). [pre-menopausal][post-menopausal] [adjuvant]  [DNA source: leukocytes] [HWE: Vietnamese *1, 2, 4, 5, 10, 41 yes Filipino *1 and *2 no rest yes] An additional nested case-control study (n=48) showed an  increased risk of recurrence at low and high (>70 ng/ml) endoxifen concentrations.",
        "Sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.",
        "Alleles": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
        "isPlural": "Are",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "decreased",
        "PD/PK terms": "concentrations of",
        "Population types": "in women with",
        "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
        "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *2/*2"
      },
      {
        "Variant Annotation ID": 1444930474,
        "Variant/Haplotypes": "CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41",
        "Gene": "CYP2D6",
        "Drug(s)": "4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen",
        "PMID": 23476897,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "no",
        "Notes": "No information on menopausal status or if tamoxifen only treatment. No co-treatment with CYP2D6 inhibitors CYP2D6 alleles *2, *3, *4, *5, *6, *10, and *41 are genotyped with predeveloped TaqMan Genotyping Assays. Genotypes were categorized as normal (fully functional CYP2D6 alleles: *1 and *2 -*1/*1, *1/*2, *2/*2), intermediate (alleles associated with reduced enzyme activity: heterozygous for *10 and *41-*1/*10, *2/*10, *1/*41), and slow (homozygous for *10, *41 variants and one or more non-functional null alleles: *3-*6-*10/*10, *10/*41, *1/*5, *2/*5, *5/*10). [pre-menopausal][post-menopausal] [adjuvant]  [DNA source: leukocytes] [HWE: Vietnamese *1, 2, 4, 5, 10, 41 yes Filipino *1 and *2 no rest yes]",
        "Sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.",
        "Alleles": "*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10",
        "isPlural": "Are",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "decreased",
        "PD/PK terms": "concentrations of",
        "Multiple drugs And/or": "and",
        "Population types": "in women with",
        "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
        "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *2/*2"
      }
    ],
    "var_pheno_ann": [],
    "var_fa_ann": []
  },
  "PMC6435416": {
    "pmid": 30661084,
    "pmcid": "PMC6435416",
    "title": "CYP2D6 genotype and adverse events to risperidone in children and adolescents.",
    "study_parameters": {
      "Study Parameters ID": 1450932850,
      "Variant Annotation ID": 1450932846,
      "Study Type": "cohort, retrospective",
      "Study Cases": 257.0,
      "Characteristics": "multivariate analysis adjusted for age, sex, race, and initial risperidone dose",
      "Characteristics Type": "Study Cohort",
      "P Value": "= 0.03",
      "Ratio Stat Type": "OR",
      "Ratio Stat": 2.4,
      "Confidence Interval Start": 1.1,
      "Confidence Interval Stop": 5.1,
      "Biogeographical Groups": "Multiple groups, White Hispanic, White non-Hispanic, African American, Asian/Pacific Islander, Native American or 'Unknown' ethnicities"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1450932846,
        "Variant/Haplotypes": "CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41",
        "Gene": "CYP2D6",
        "Drug(s)": "risperidone",
        "PMID": 30661084,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "Normal metabolizer also included: *35/*35 + *2/*9 + *2/*3 + *2/*29 + *2/*10 + *1xN/*4 + *10/*46 + *10/*35 + *1/*6 + *1/*33 + *1/*10 + *4/*35. Most common AEs were weight change (9%), sedation (6%), and extrapyramidal symptoms (6%). Of the 224 normal/ultrarapid metabolizers, 20 (9%) were taking one or more concomitant drugs that are known strong inhibitors of CYP2D6. The frequency of AEs was not different among those with a strong concomitant CYP2D6 inhibitor (6/20, 30%) vs. those without (55/204, 27%, P= 0.8). CYP2D6 phenoconversion not considered in the PM+IM vs NM+UM analysis.",
        "Sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .",
        "Alleles": "*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17",
        "Specialty Population": "Pediatric",
        "Metabolizer types": "intermediate metabolizer and poor metabolizer",
        "isPlural": "Are",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:adverse events",
        "When treated with/exposed to/when assayed with": "due to",
        "Population types": "in children",
        "Comparison Allele(s) or Genotype(s)": "*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1",
        "Comparison Metabolizer types": "normal metabolizer and ultrarapid metabolizer"
      }
    ],
    "var_fa_ann": []
  },
  "PMC11971672": {
    "pmid": 40184070,
    "pmcid": "PMC11971672",
    "title": "Cytochrome P450 2C19 Genotypes and Clopidogrel in Patients With Ischemic Stroke: A Nonrandomized Clinical Trial.",
    "study_parameters": {
      "Study Parameters ID": 1453096116,
      "Variant Annotation ID": 1453096120,
      "Study Type": "clinical trial",
      "Study Cases": 2910.0,
      "Characteristics": "PLATELET trial, composite outcome (recurrent stroke, myocardial infarction, and all-cause mortality at 180 days)",
      "Characteristics Type": "Study Cohort",
      "P Value": "= 0.048",
      "Ratio Stat Type": "HR",
      "Ratio Stat": 0.58,
      "Confidence Interval Start": 0.34,
      "Confidence Interval Stop": 1.0,
      "Biogeographical Groups": "Unknown"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1453096120,
        "Variant/Haplotypes": "CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17",
        "Gene": "CYP2C19",
        "Drug(s)": "clopidogrel",
        "PMID": 40184070,
        "Phenotype Category": "Efficacy",
        "Significance": "yes",
        "Notes": "\"Overall, 49 of 1785 LOF allele carriers (2.7%) and 18 of 1125 LOF allele noncarriers (1.6%) experienced cardiovascular events, defined as a composite of recurrent stroke, myocardial infarction, and all-cause mortality at 180 days...The primary outcome of composite cardiovascular events occurred significantly more in the LOF allele carrier group (49 of 1785 [2.7%]) compared with the noncarrier group (18 of 1125 [1.6%]) (HR, 0.58; 95% CI, 0.34-1.00; P\u2009=\u2009.048 for log-rank test).\"",
        "Sentence": "CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) .",
        "Alleles": "*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3",
        "Metabolizer types": "intermediate metabolizer and poor metabolizer",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in people with",
        "Population Phenotypes or diseases": "Other:Stroke",
        "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*17 + *17/*17",
        "Comparison Metabolizer types": "normal metabolizer"
      }
    ],
    "var_fa_ann": []
  },
  "PMC12036300": {
    "pmid": 40295977,
    "pmcid": "PMC12036300",
    "title": "The frequencies of CYP2C19*2, *3, and *17 alleles and their impact on the clinical efficacy of doubled maintenance dose of clopidogrel in Syrian patients with coronary artery disease.",
    "study_parameters": {
      "Study Parameters ID": 1454052120,
      "Variant Annotation ID": 1454052100,
      "Study Cases": 41.0,
      "Characteristics": "MACE, DAPT with a double maintenance dose of clopidogrel 150 mg/day (for at least one month after PCI).",
      "Characteristics Type": "Study Cohort",
      "Frequency In Cases": 0.08,
      "Allele Of Frequency In Cases": "*2",
      "P Value": "= 0.2744",
      "Biogeographical Groups": "Near Eastern"
    },
    "var_drug_ann": [],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1454052100,
        "Variant/Haplotypes": "CYP2C19*1, CYP2C19*2, CYP2C19*17",
        "Gene": "CYP2C19",
        "Drug(s)": "clopidogrel",
        "PMID": 40295977,
        "Phenotype Category": "Efficacy",
        "Significance": "no",
        "Notes": "\"Among patients who underwent PCI and were treated with a double maintenance dose of clopidogrel, the carrier status of the CYP2C19*2 allele does not appear to be associated with an increased risk of MACE.\" \"Overall, two of the 41 patients who were followed up in the study experienced at least one MACE after PCI. One case was from the CYP2C19*2 allele carrier group and the other was from the non-carrier group. In terms of the distribution of MACE based on CYP2C19*2 status, there was no statistically significant correlation (P\u2009=\u20090.2744).\"",
        "Sentence": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.",
        "Alleles": "*1/*2 + *2/*2 + *2/*17",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Major Adverse Cardiac Events (MACE)",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Comparison Allele(s) or Genotype(s)": "*1/*1"
      },
      {
        "Variant Annotation ID": 1454052160,
        "Variant/Haplotypes": "CYP2C19*1, CYP2C19*2, CYP2C19*17",
        "Gene": "CYP2C19",
        "Drug(s)": "clopidogrel",
        "PMID": 40295977,
        "Phenotype Category": "Efficacy",
        "Significance": "no",
        "Notes": "\"Our results indicated that carriers of the CYP2C19*17 variant experienced a higher incidence of bleeding events (16.67%) compared to non-carriers (6.9%). Despite this observed difference, it is important to note that the statistical analysis found no significant difference between the two groups (P\u2009=\u20090.567; see Table 7). Similarly, there was no statistically significant difference in bleeding events between CYP2C19*2 carriers and non-carriers (P\u2009=\u20090.0952; see Table 7), although a higher proportion of bleeding events was observed among carriers.\"",
        "Sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.",
        "Alleles": "*1/*17 + *17/*17 + *2/*17",
        "isPlural": "Is",
        "Is/Is Not associated": "Not associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Hemorrhage",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Comparison Allele(s) or Genotype(s)": "*1/*1"
      }
    ],
    "var_fa_ann": []
  },
  "PMC10880264": {
    "pmid": 38377518,
    "pmcid": "PMC10880264",
    "title": "Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study.",
    "study_parameters": {
      "Study Parameters ID": 1452390351,
      "Variant Annotation ID": 1452390346,
      "Study Cases": 48.0,
      "Characteristics": "Outpatient youth aged 12\u201317 years who had at least one first-degree relative with bipolar I disorder; dose-normalized AUC0\u201324",
      "Characteristics Type": "Study Cohort",
      "P Value": "= 0.025",
      "Biogeographical Groups": "Multiple groups, Non-Hispanic Caucasian n=33, Hispanic Caucasian n=6, Black or African n = 6, Multiple or other n=6"
    },
    "var_drug_ann": [
      {
        "Variant Annotation ID": 1452390346,
        "Variant/Haplotypes": "CYP2C19 intermediate metabolizer",
        "Gene": "CYP2C19",
        "Drug(s)": "escitalopram",
        "PMID": 38377518,
        "Phenotype Category": "Metabolism/PK",
        "Significance": "yes",
        "Notes": "CPIC guidelines used to assign CYP2C19  metabolizer phenotypes based on CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17. \"CYP2C19 metabolizer phenotype had a significant effect on the dose-normalized AUC0\u201324 (p\u2009=\u20090.025), Ctrough (p\u2009=\u20090.013), and t1/2 (p\u2009=\u20090.0008) of escitalopram (Fig. 1).\u201d \"CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n\u2009=\u200917), normal metabolizer (NM n\u2009=\u200931), or intermediate metabolizer (IM n\u2009=\u200917), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).\"",
        "Sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-adjusted trough concentrations of escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.",
        "Specialty Population": "Pediatric",
        "Metabolizer types": "intermediate metabolizer",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "PD/PK terms": "dose-adjusted trough concentrations of",
        "Population types": "in children with",
        "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
        "Multiple phenotypes or diseases And/or": "or",
        "Comparison Metabolizer types": "normal metabolizer"
      }
    ],
    "var_pheno_ann": [
      {
        "Variant Annotation ID": 1452390389,
        "Variant/Haplotypes": "CYP2D6 poor metabolizer",
        "Gene": "CYP2D6",
        "Drug(s)": "escitalopram",
        "PMID": 38377518,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"Slower CYP2D6 phenotypes were significantly associated with greater increases in TEASAP Akathisia, Hyperkinesis, and Somatic Anxiety subscale (p\u2009=\u20090.015; Fig. 2), but not with other TEASAP subscales\" \"participants with slower than normal CYP2D6 metabolism had significantly greater TEASAP disinhibition and impulsivity subscale scores than those with normal or faster than normal metabolism (mean\u2009=\u20093.0 vs. 1.1, p\u2009=\u20090.02).\" \"CYP2D6 metabolizer phenotypes were predominantly normal (NM n\u2009=\u200943) or intermediate (IM n\u2009=\u200915), with few ultrarapid (UM n\u2009=\u20092) or poor (PM n\u2009=\u20094) metabolizers. Two participants were excluded from CYP2D6-related analyses because genetic testing indicated gene duplications without revealing which allele was duplicated, thus precluding a definitive interpretation of CYP2D6 phenotype\" Alleles measured :CYP2D6: *1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *41, gene duplication.",
        "Sentence": "CYP2D6 poor metabolizer is associated with increased likelihood of Psychomotor Agitation, Hyperkinesis or Impulse control disorder, unspecified when treated with escitalopram in children with Depression or Anxiety Disorders as compared to CYP2D6 normal metabolizer.",
        "Specialty Population": "Pediatric",
        "Metabolizer types": "poor metabolizer",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:Psychomotor Agitation, Side Effect:Hyperkinesis, Side Effect:Impulse control disorder",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in children with",
        "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
        "Multiple phenotypes or diseases And/or": "or",
        "Comparison Metabolizer types": "normal metabolizer"
      },
      {
        "Variant Annotation ID": 1452390301,
        "Variant/Haplotypes": "CYP2C19 intermediate metabolizer",
        "Gene": "CYP2C19",
        "Drug(s)": "escitalopram",
        "PMID": 38377518,
        "Phenotype Category": "Toxicity",
        "Significance": "not stated",
        "Notes": "CPIC guidelines used to assign CYP2C19  metabolizer phenotypes based on CYP2C19: *1, *2,*3, *4, *5, *6, *7, *8, *17. \"Slower CYP2C19 metabolizers tended to have greater TEASAP \u201cself-injury, suicidality, and harm to others\u201d subscale scores (F\u2009=\u20092.32, df\u2009=\u20092, p\u2009=\u20090.09), though CYP2C19 phenotype was not associated with increases in other TEASAP subscales scores\" \"CYP2C19 metabolizer phenotypes were almost exclusively rapid metabolizer (RM n\u2009=\u200917), normal metabolizer (NM n\u2009=\u200931), or intermediate metabolizer (IM n\u2009=\u200917), with only one ultrarapid metabolizer (UM) and no poor metabolizers (PMs).\"",
        "Sentence": "CYP2C19 intermediate metabolizer is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.",
        "Specialty Population": "Pediatric",
        "Metabolizer types": "intermediate metabolizer",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in children with",
        "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
        "Multiple phenotypes or diseases And/or": "or",
        "Comparison Metabolizer types": "normal metabolizer"
      },
      {
        "Variant Annotation ID": 1452390352,
        "Variant/Haplotypes": "rs6311",
        "Gene": "HTR2A",
        "Drug(s)": "escitalopram",
        "PMID": 38377518,
        "Phenotype Category": "Toxicity",
        "Significance": "yes",
        "Notes": "\"Participants with HTR2A A/A or A/G genotypes had a greater increase in TEASAP \u201cSelf-injury, Suicidality, and Harm to Others\u201d subscale scores relative to those with HTR2A G/G genotypes (p\u2009=\u20090.017)\" Alleles complemented.",
        "Sentence": "Genotypes CT + TT (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to genotype CC (assigned as normal metabolizer phenotype) .",
        "Alleles": "CT + TT",
        "Specialty Population": "Pediatric",
        "Metabolizer types": "intermediate metabolizer",
        "isPlural": "Is",
        "Is/Is Not associated": "Associated with",
        "Direction of effect": "increased",
        "Side effect/efficacy/other": "likelihood of",
        "Phenotype": "Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm",
        "Multiple phenotypes And/or": "or",
        "When treated with/exposed to/when assayed with": "when treated with",
        "Population types": "in children with",
        "Population Phenotypes or diseases": "Other:Depression, Other:Anxiety Disorders",
        "Multiple phenotypes or diseases And/or": "or",
        "Comparison Allele(s) or Genotype(s)": "CC",
        "Comparison Metabolizer types": "normal metabolizer"
      }
    ],
    "var_fa_ann": []
  }
}